[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 74 of about 74
1. Bruin SC, Klijn C, Liefers GJ, Braaf LM, Joosse SA, van Beers EH, Verwaal VJ, Morreau H, Wessels LF, van Velthuysen ML, Tollenaar RA, Van't Veer LJ: Specific genomic aberrations in primary colorectal cancer are associated with liver metastases. BMC Cancer; 2010;10:662
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific genomic aberrations in primary colorectal cancer are associated with liver metastases.
  • BACKGROUND: Accurate staging of colorectal cancer (CRC) with clinicopathological parameters is important for predicting prognosis and guiding treatment but provides no information about organ site of metastases.
  • Patterns of genomic aberrations in primary colorectal tumors may reveal a chromosomal signature for organ specific metastases.
  • METHODS: Array Comparative Genomic Hybridization (aCGH) was employed to asses DNA copy number changes in primary colorectal tumors of three distinctive patient groups.
  • This included formalin-fixed, paraffin-embedded tissue of patients who developed liver metastases (LM; n = 36), metastases (PM; n = 37) and a group that remained metastases-free (M0; n = 25).A novel statistical method for identifying recurrent copy number changes, KC-SMART, was used to find specific locations of genomic aberrations specific for various groups.
  • RESULTS: Specifically in the tumors of primary CRC patients who subsequently developed liver metastasis, KC-SMART analysis identified genomic aberrations on chromosome 20q.
  • LM-PAM, a shrunken centroids classifier for liver metastases occurrence, was able to distinguish the LM group from the other groups (M0&PM) with 80% accuracy (78% sensitivity and 86% specificity).
  • CONCLUSION: Liver specific CRC metastases may be predicted with a high accuracy based on specific genomic aberrations in the primary CRC tumor.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 20. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Gene Dosage. Liver Neoplasms / genetics. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Comparative Genomic Hybridization. Databases, Genetic. Female. Fixatives. Formaldehyde. Gene Expression Profiling / methods. Genetic Predisposition to Disease. Humans. Logistic Models. Male. Middle Aged. Neoplasm Staging. Netherlands. Oligonucleotide Array Sequence Analysis. Paraffin Embedding. Phenotype. Predictive Value of Tests. Survival Analysis. Time Factors. Tissue Fixation / methods. Treatment Outcome


2. Rivera L, Giap H, Miller W, Fisher J, Hillebrand DJ, Marsh C, Schaffer RL: Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. World J Gastroenterol; 2006 Sep 21;12(35):5729-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report.
  • Hepatocellular carcinoma (HCC) recurs with a reported frequency of 12%-18% after liver transplantation.
  • Approximately one-third of recurrences develop in the transplanted liver and are therefore amenable to local therapy.
  • Yttrium-90 microspheres have been used as a treatment modality both for primary HCC and for pre-transplant management of HCC with promising results.
  • Twenty-two months after liver transplantation for hepatitis C cirrhosis complicated by HCC, a 42-year old man developed recurrence of HCC in his transplant allograft.
  • Multifocal recurrence in the remaining liver allograft was treated with hepatic intra-arterial infusion of yttrium-90 microspheres (SIR-Spheres, Sirtex Medical Inc., Lake Forest, IL, USA).
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Hepatitis C. Humans. Infusions, Intra-Arterial. Liver Transplantation. Male. Microspheres. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1747-52 [11920537.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S223-9 [12354840.001]
  • [Cites] Transplantation. 2002 Dec 27;74(12):1746-51 [12499891.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S107-10 [14762849.001]
  • [Cites] Psychooncology. 2004 Feb;13(2):73-9 [14872525.001]
  • [Cites] Liver Transpl. 2005 Sep;11(9):1127-31 [16123954.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):195-203 [15713920.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):205-13 [15713921.001]
  • [Cites] Arch Surg. 2005 Apr;140(4):353-8 [15837885.001]
  • [Cites] Liver Transpl. 2004 Apr;10(4):534-40 [15048797.001]
  • (PMID = 17007031.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  • [Other-IDs] NLM/ PMC4088179
  •  go-up   go-down


3. Tomimaru Y, Nagano H, Marubashi S, Kobayashi S, Eguchi H, Takeda Y, Tanemura M, Kitagawa T, Umeshita K, Hashimoto N, Yoshikawa H, Wakasa K, Doki Y, Mori M: Sclerosing epithelioid fibrosarcoma of the liver infiltrating the inferior vena cava. World J Gastroenterol; 2009 Sep 7;15(33):4204-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing epithelioid fibrosarcoma of the liver infiltrating the inferior vena cava.
  • We report a 39-year-old man with SEF of the liver, which infiltrated the inferior vena cava (IVC).
  • The SEF of the liver was successfully resected, and the infiltrated IVC was also removed together with the liver tumor.
  • After chemotherapy, the recurrent tumor was resected surgically, and histopathological examination showed similar findings to those of the primary tumor.
  • To our knowledge, this is the first report of SEF of the liver with tumor invasion of the IVC.
  • [MeSH-major] Epithelioid Cells / pathology. Fibrosarcoma / pathology. Liver Neoplasms / pathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Sclerosis

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2004 Jan;57(1):90-4 [14693846.001]
  • [Cites] Cancer. 1994 May 15;73(10):2653-62 [8174066.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):502-8 [7951320.001]
  • [Cites] Am J Surg Pathol. 1995 Sep;19(9):979-93 [7661286.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Dec;107(2):102-6 [9844602.001]
  • [Cites] Presse Med. 1954 May 5;62(33):709-12 [13177441.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):227-30 [12232581.001]
  • [Cites] Arch Pathol Lab Med. 2007 Dec;131(12):1825-8 [18081443.001]
  • [Cites] Endocr Pathol. 2007 Winter;18(4):233-8 [18097772.001]
  • [Cites] Clin Orthop Relat Res. 2008 Jun;466(6):1485-91 [18340502.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):956-9; discussion 959-60 [11014436.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):699-709 [11395547.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2005 Feb;114(2):87-9 [15757185.001]
  • (PMID = 19725160.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2738822
  •  go-up   go-down


Advertisement
4. Fu DL, Yang F, Maskay A, Long J, Jin C, Yu XJ, Xu J, Zhou ZW, Ni QX: Primary intestinal malignant fibrous histiocytoma: two case reports. World J Gastroenterol; 2007 Feb 28;13(8):1299-302
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intestinal malignant fibrous histiocytoma: two case reports.
  • Here we report two cases of primary intestinal MFH.
  • The first case was a 70-year old man admitted for recurrent right lower quadrant abdominal pain.
  • At laparotomy, a tumor was found originating from the cecum, with a suspicious metastatic nodule on the surface of the right lobe of the liver.
  • [MeSH-minor] Adult. Aged. Cecum / pathology. Fatal Outcome. Humans. Intestine, Small / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Burns. 2000 May;26(3):305-10 [10741601.001]
  • [Cites] Surg Today. 2005;35(4):323-7 [15815852.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Skeletal Radiol. 2003 Nov;32(11):613-8 [14517697.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1156-60 [15387338.001]
  • [Cites] Burns. 2004 Nov;30(7):742-5 [15475153.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Gastroenterol Jpn. 1993 Aug;28(4):554-63 [7690726.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):91-6 [8548744.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Pathol Int. 1997 Oct;47(10):718-24 [9361108.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 15;100(2):134-42 [9428357.001]
  • [Cites] Surg Today. 1999;29(2):160-4 [10030742.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):447-8 [10419723.001]
  • [Cites] APMIS. 1999 Sep;107(9):837-42 [10519319.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Surg Today. 2001;31(3):242-5 [11318129.001]
  • (PMID = 17451221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4147015
  •  go-up   go-down


5. Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, Borsellino N, Colucci G: Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.). Anticancer Res; 2005 Nov-Dec;25(6C):4445-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
  • BACKGROUND: The combination of cisplatin (CDDP) and 5-Fluorouracil (5-FU) is a standard regimen for the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
  • Raltitrexed (R) is a potent and specific thymidylate synthase inhibitor with activity comparable to that of 5-FU in colorectal cancer; moreover, it showed activity as a single agent in HNSCC.
  • MATERIALS AND METHODS: Since 2001, a multicentre, phase II trial has been underway to evaluate the efficacy and toxicity of the CB+R combination in untreated patients with recurrent or metastatic HNSCC.
  • Patients had a histo/cytologically proven recurrent or metastatic HNSCC; patients with locally advanced disease not amenable to CDDP+5-FU treatment were also included.
  • Patients had to be >18 years old with ECOG PS of 0-2 and adequate bone marrow, renal and liver functions.
  • Twelve patients were staged III and 20 were metastatic (10 recurrent).
  • The oral cavity/oropharynx were the primary site in 20 patients and the larynx in 10 patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Female. Humans. Male. Middle Aged. Quinazolines / administration & dosage. Quinazolines / adverse effects. Survival Rate. Thiophenes / administration & dosage. Thiophenes / adverse effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334124.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; BG3F62OND5 / Carboplatin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


6. Kwon JB, Park K, Kim YD, Seo JH, Moon SW, Cho DG, Kim YW, Kim DG, Yoon SK, Lim HW: Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors. World J Gastroenterol; 2008 Oct 7;14(37):5717-22
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors.
  • At the end of the follow-up, 1 patient died from hepatic failure without recurrence, 6 died from hepatic failure with a recurrent hepatocellular carcinoma (HCC), and 4 died from recurrent HCC with cachexia.
  • Among several clinical factors, Kaplan-Meier analysis revealed that liver transplantation as a treatment for the primary lesion, grade of cell differentiation, and negative evidence HBV infection were independent predictive factors.
  • Although not significant, patients with liver transplantation of a primary HCC survived longer.
  • Liver transplantation might be the most beneficial modality that can offer patients better survival.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / therapy. Lung Neoplasms / surgery. Pulmonary Surgical Procedures
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cell Differentiation. Female. Hepatectomy. Hepatitis B / complications. Humans. Kaplan-Meier Estimate. Liver Transplantation / adverse effects. Male. Middle Aged. Patient Selection. Proportional Hazards Models. Risk Assessment. Risk Factors. Thoracoscopy. Thoracotomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):251-7 [9058154.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):720-6 [8780578.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1198-200 [9752858.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Nov;54(5):415-20 [15235823.001]
  • [Cites] J Chin Med Assoc. 2004 Dec;67(12):621-4 [15779485.001]
  • [Cites] World J Surg. 2005 Jun;29(6):715-8 [16078127.001]
  • [Cites] J Hepatol. 2005 Oct;43(4):584-9 [16120468.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7 [16246200.001]
  • [Cites] Am J Surg. 2006 Jul;192(1):46-51 [16769274.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):152-6 [17419251.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Jul 1;26(1):87-94 [17555425.001]
  • [Cites] J Thorac Cardiovasc Surg. 1965 Mar;49:357-63 [14265951.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1815-20 [10585064.001]
  • [Cites] Radiology. 2000 Sep;216(3):698-703 [10966697.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1088-93 [11490807.001]
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):311-8 [12229937.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1688-9 [15162554.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):825-9 [15143926.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(3):386-8 [12353153.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1428-33 [15362769.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1123-39, ix [15488562.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):401-5 [6198058.001]
  • [Cites] Semin Surg Oncol. 1990;6(5):297-302 [2237090.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):316-9 [7691699.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):86-92 [9683759.001]
  • (PMID = 18837090.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2748208
  •  go-up   go-down


7. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ: Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biol Blood Marrow Transplant; 2010 Aug;16(8):1145-54
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
  • Autologous hematopoietic cell transplantation with augmented BCNU regimens is effective treatment for recurrent or refractory Hodgkin lymphoma (HL); however, BCNU-related toxicity and disease recurrence remain challenges.
  • The primary endpoint was the incidence of BCNU-related toxicity.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol. 1998 Sep;16(3):101-5 [10235068.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S103-8 [9926247.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(11):1131-8 [10382952.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):116-23 [15598948.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Jan;11(1):13-22 [15625540.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(5):429-35 [15654355.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1160-8 [15939713.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1473-8 [15870180.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72 [17084370.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Cancer. 2007 Jun 15;109(12):2481-9 [17497648.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1071-9 [17426059.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3746-52 [17646666.001]
  • [Cites] Bone Marrow Transplant. 2008 Apr;41(7):613-9 [18071290.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5980-7 [19018090.001]
  • [Cites] Oncologist. 2009 Apr;14(4):425-32 [19342476.001]
  • [Cites] Br J Haematol. 2009 May;145(3):369-72 [19344403.001]
  • [Cites] Br J Haematol. 2009 Jul;146(2):158-63 [19438504.001]
  • [Cites] Biol Blood Marrow Transplant. 1999;5(5):292-8 [10534059.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2627-8 [10561333.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):405-11 [10637256.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):73-9 [10690391.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1353-8 [10717616.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(4):387-94 [10917574.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(1):49-57 [11215699.001]
  • [Cites] Blood. 2001 Feb 1;97(3):616-23 [11157476.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(10):552-60 [11760087.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] Semin Liver Dis. 2002 Feb;22(1):27-42 [11928077.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Ann Hematol. 2002 Aug;81(8):424-9 [12223998.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1628-35 [12377653.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Aug;9(8):529-39 [12931122.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1762-7 [14630682.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Nov;10(11):794-804 [15505610.001]
  • [Cites] J Clin Oncol. 1983 Oct;1(10):610-20 [6366127.001]
  • [Cites] Ann Intern Med. 1986 Feb;104(2):163-8 [3511811.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):648-56 [2313334.001]
  • [Cites] J Clin Oncol. 1991 Oct;9(10):1871-9 [1919637.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):406-13 [1740680.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] Chest. 1995 Feb;107(2):482-7 [7842781.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1381-90 [7858268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):3-12 [8823253.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):409-14 [8882953.001]
  • [Cites] Blood. 1997 Feb 1;89(3):801-13 [9028311.001]
  • [Cites] Blood. 1997 Feb 1;89(3):814-22 [9028312.001]
  • [Cites] Biol Blood Marrow Transplant. 1997 Jun;3(2):98-106 [9267670.001]
  • [Cites] Invest New Drugs. 1997;15(4):331-41 [9547676.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):533-5 [9827930.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S97-101 [9926246.001]
  • [Cites] Invest New Drugs. 1998-1999;16(3):275-8 [10360609.001]
  • (PMID = 20197102.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA049605-21; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / P01 CA049605-21; United States / NCI NIH HHS / CA / P01 CA49605
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS196586; NLM/ PMC2921221
  •  go-up   go-down


8. Pessaux P, Lermite E, Brehant O, Tuech JJ, Lorimier G, Arnaud JP: Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol; 2006 Jan 1;93(1):1-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeat hepatectomy for recurrent colorectal liver metastases.
  • PURPOSE: Liver resection represents the best and potentially curative treatment for metastatic colorectal cancer (MCC) to the liver.
  • After resection, however, most patients develop recurrent disease, often isolated to the liver.
  • The aim of this study was to determine the value of repeat liver resection for recurrent MCC and to analyze the factors that can predict survival.
  • The primary tumor was carcinoma of the colon in 26 patients and carcinoma of the rectum in 16 patients.
  • Liver metastases were synchronous in 24 patients (57.1%).
  • [MeSH-major] Colonic Neoplasms / pathology. Hepatectomy / methods. Hepatectomy / mortality. Liver Neoplasms / secondary. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Reoperation / mortality. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16353192.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH: Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol; 2007 Jan;62(1):28-34; discussion 35-6
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis.
  • AIM: To evaluate patterns of disease and identify factors predicting outcome in patients presenting with recurrent endometrial adenocarcinoma following primary surgery.
  • MATERIALS AND METHODS: A retrospective review was performed of the imaging and clinical data in 86 patients (median age 66 years, range 42-88 years) presenting with recurrent endometrial adenocarcinoma following primary surgery.
  • RESULTS: Following primary surgery recurrent disease occurred within 2 years in 64% and within 3 years in 87%.
  • Univariate survival analysis showed the factors significant for poor outcome were: multiple sites of disease, liver and splenic disease, haematogenous, peritoneal and nodal spread, poorly differentiated tumour, and early relapse.
  • Multivariate analysis identified multiple sites of disease, liver and splenic metastases to be independent predictors of poor outcome.
  • Significant predictors of poor outcome in recurrent disease are multiple sites of disease and liver and splenic metastases.
  • [MeSH-major] Adenocarcinoma / radiography. Endometrial Neoplasms / radiography. Neoplasm Recurrence, Local / radiography. Neoplasms, Multiple Primary / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hysterectomy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Neoplasm Staging. Peritoneal Neoplasms / radiography. Peritoneal Neoplasms / secondary. Prognosis. Retrospective Studies. Splenic Neoplasms / radiography. Splenic Neoplasms / secondary. Vaginal Neoplasms / radiography. Vaginal Neoplasms / secondary

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145260.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, Li H, Hao X: Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg; 2008 Sep;12(9):1540-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma.
  • AIMS: To clarify the incidence of multicentric occurrence (MO) and intrahepatic metastasis (IM) for hepatocellular carcinoma (HCC) related to hepatitis B virus in China and to identify the differences between them.
  • METHODS: Histopathologic and genetic features of primary and recurrent tumors in 160 cases with HCC were analyzed.
  • By comparing the genetic information of loss of heterozygosity and microsatellite instability for 10 different markers between primary and recurrent tumor, 30.0% and 63.8% patients with recurrent HCC were considered to be MO and IM, respectively.
  • CONCLUSIONS: Combined analysis of histopathological and genetic analysis may reflect more exactly the nature of recurrent HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Hepatitis B / epidemiology. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Age Distribution. Biopsy, Needle. China / epidemiology. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Multivariate Analysis. Neoplasm Staging. Polymerase Chain Reaction. Probability. Regression Analysis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18629593.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Yoon YS, Kim SW, Jang JY, Park YH: Curative reoperation for recurrent cancer of the extrahepatic bile duct: report of two cases. Hepatogastroenterology; 2005 Mar-Apr;52(62):381-4
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative reoperation for recurrent cancer of the extrahepatic bile duct: report of two cases.
  • Local recurrence, following a resection for cancer of the extrahepatic bile duct, is usually incurable with second curative surgery being almost impossible.
  • The medical records and clinical outcomes of two patients that underwent a re-resection for recurrent cancer of the extrahepatic bile duct were retrospectively reviewed.
  • A 50-year-old female patient that had a recurrent disease at the intrahepatic and intrapancreatic bile duct, 66 months after a segmental resection of the bile duct for common bile duct (CBD) cancer, underwent a hepatopancreatoduodenectomy.
  • A 29-year-old female patient had a recurrent tumor mass in the distal CBD, 28 months after a right hemihepatectomy and Roux-en-Y hepaticojejenostomy for a type IIIa Klatskin tumor, and underwent a segmental resection of the bile duct.
  • It is concluded that a surgical re-resection is possible in selected patients with recurrent bile duct cancer, mostly of the papillary type.
  • A primary operation for bile duct cancer should be performed with a wide surgical margin, and secondary curative surgery should be considered whenever possible in cases of recurrence.
  • [MeSH-minor] Adult. Cholangiography. Female. Hepatectomy. Humans. Jejunostomy. Liver / surgery. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy. Reoperation. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Extrahepatic bile duct cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816441.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Fanfani F, Fagotti A, Gallotta V, Ercoli A, Pacelli F, Costantini B, Vizzielli G, Margariti PA, Garganese G, Scambia G: Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol Oncol; 2010 Mar;116(3):497-501
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery.
  • OBJECTIVE: Upper abdominal spread of primary and recurrent ovarian cancer is often considered to be a major obstacle to achieve optimal residual disease at the end of surgery.
  • In this study, we investigate the role of diaphragmatic debulking in the natural history of advanced and recurrent epithelial ovarian cancer patients, and the morbidity of this procedure according to clinico-surgical characteristics.
  • METHODS: Data from 234 consecutive patients with primary and recurrent advanced ovarian cancer, operated at Catholic University of Rome and Campobasso from January 1, 2005 and December 31, 2008, were retrospectively reviewed.
  • Diaphragmatic debulking was performed in 50 out of 120 patients at primary surgery (41.7%), in 16 out of 74 at interval debulking surgery (21.6%) and in 21 out of 40 secondary cytoreductions (52.5%).
  • Presence of a post-operative pleural effusion was correlated liver mobilization (52.3% vs. 16%; p<0.0027) and large diaphragmatic disease (>5 cm) removal (54.1% vs. 23.5%; p<0.034).
  • CONCLUSIONS: Diaphragmatic surgery represents a crucial step in the debulking of advanced and recurrent ovarian cancer patients.
  • Considering the natural history of advanced epithelial ovarian cancer and the rate of patients needing diaphragmatic debulking during primary cytoreduction, interval debulking surgery and secondary cytoreduction, this procedure should be present in the surgical repertoire of a gynecologic oncologist.
  • [MeSH-minor] Abdomen / pathology. Abdomen / surgery. Adult. Aged. Disease-Free Survival. Female. Gynecologic Surgical Procedures / adverse effects. Gynecologic Surgical Procedures / methods. Humans. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20004958.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Mizutani S, Oyama T, Hatanaka N, Uchikoshi F, Yoshidome K, Tori M, Ueshima S, Okuma K, Hiraoka K, Yamagami Y, Takahashi H, Sueyoshi K, Taira M, Nakahara M, Nakao K: [Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers]. Gan To Kagaku Ryoho; 2006 Mar;33(3):327-31
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers].
  • We conducted combined therapy of weekly paclitaxel and doxifluridine (5'-DFUR) for 23 cases of advanced and recurrent gastric carcinomas to investigate their efficacy and safety.
  • Subjects included 7 unresectable cases, 5 noncurative resection cases, and 11 recurrent cases.
  • One of the CR cases was an unresectable case involving a primary tumor, liver metastasis, and abdominal lymph node metastasis, while the other was a recurrent case involving abdominal lymph node metastasis.
  • Combination therapy of weekly paclitaxel and 5'-DFUR can be an effective and safe therapy for advanced and recurrent gastric carcinomas.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Floxuridine / administration & dosage. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531712.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


14. Ribeiro MA Jr, Rodrigues JJ, Habr-Gama A, Chaib E, D'Ipolitto G, Fonseca AZ, Saad WA Jr, Saad WA: Radiofrequency ablation of primary and metastatic liver tumors--4 years experience. Hepatogastroenterology; 2007 Jun;54(76):1170-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of primary and metastatic liver tumors--4 years experience.
  • BACKGROUND/AIMS: Radiofrequency ablation of primary and metastatic liver tumors has been shown to be one of the promising new modalities to treat or to palliate liver tumors.
  • It has been used as a bridge to liver transplantation as well as an approach to recurrent tumors after resection.
  • There were 32 cases of hepatocellular carcinoma, 35 metastases of colorectal cancer and 11 cases of other tumors.
  • All liver segments were compromised specially IV, VII, VIII.
  • CONCLUSIONS: The RFA procedure is safe, can be performed by different ways and in the group of patients who are candidates to liver transplantation, while waiting for the organ.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629064.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Hashimoto K, Ueno H, Ikeda M, Kojima Y, Hagihara A, Kondo S, Morizane C, Okusaka T: Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology; 2009;77(3-4):217-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
  • BACKGROUND: Whether recurrence after surgery and primary metastatic pancreatic cancer should be included in the same category when conducting gemcitabine-based clinical trials remains controversial.
  • OBJECTIVE: To clarify the outcomes of recurrent and metastatic pancreatic cancers.
  • METHODS: 326 patients who received gemcitabine monotherapy as a first-line treatment for advanced pancreatic cancer between 2001 and 2007 were reviewed.
  • RESULTS: There were 65 recurrent and 261 metastatic cancer patients.
  • Recurrent cancer patients had a significantly longer time to treatment failure and survival (respective medians 138 and 77 days, p = 0.017) than the metastatic patients (respective medians 270 and 185 days, p = 0.0003).
  • Multivariate analysis revealed poor Karnofsky performance status (<80), presence of liver or peritoneal metastasis, elevated lactate dehydrogenase (>220 U/l), elevated alkaline phosphatase (>330 U/l) and elevated C-reactive protein (>1.0 mg/dl) to be significantly correlated with short survival, while neither recurrent nor metastatic status were related to survival (hazard ratio 0.76, 95% CI 0.53-1.09, p = 0.14).
  • CONCLUSION: When conducting clinical trials, it appears to be acceptable to treat recurrent pancreatic cancer after surgery and pancreatic cancer with primary metastasis under the same category.
  • [MeSH-minor] Adult. Aged. C-Reactive Protein / analysis. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19729980.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 9007-41-4 / C-Reactive Protein; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


16. Abood G, Bowen M, Potkul R, Aranha G, Shoup M: Hepatic resection for recurrent metastatic ovarian cancer. Am J Surg; 2008 Mar;195(3):370-3; discussion 373
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for recurrent metastatic ovarian cancer.
  • BACKGROUND: The role for liver resection in metastatic ovarian cancer has not been defined.
  • The aim of the current study was to investigate the validity of hepatic resection as a treatment option in metastatic ovarian cancer.
  • METHODS: Retrospective review of a single institution's experience of patients undergoing hepatic resection for metastatic ovarian cancer from 1998-2006.
  • RESULTS: Ten patients underwent resection for metastatic ovarian cancer.
  • Primary tumor type included serous cystadenocarcinoma (n = 8), granulosa cell (n = 1), and yolk sac (n = 1).
  • Liver resections included trisegmentectomy (n = 4), lobectomy (n = 4), and bisegmentectomy(n = 1).
  • The median overall survival following liver resection was 33 months.
  • CONCLUSION: Liver resection for metastatic ovarian cancer is safe and is associated with long-term survival in some patients.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cystadenocarcinoma / secondary. Cystadenocarcinoma / surgery. Endodermal Sinus Tumor / secondary. Endodermal Sinus Tumor / surgery. Female. Granulosa Cell Tumor / secondary. Granulosa Cell Tumor / surgery. Humans. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207130.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


17. Xu L, Zhou Y, Qiu D: Correlation between calcified liver metastases and histopathology of primary colorectal carcinoma in Chinese. J Huazhong Univ Sci Technolog Med Sci; 2010 Dec;30(6):815-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between calcified liver metastases and histopathology of primary colorectal carcinoma in Chinese.
  • The study examined the association between calcified liver metastases and the histopathology of the primary colorectal carcinoma in Chinese.
  • The clinical, pathological and CT data were retrospectively analyzed in 210 patients (mean age: 54.2 years) with liver metastases from colorectal carcinoma.
  • All patients had no history of chronic liver diseases and had never received interventional treatments.
  • χ(2)-test was used to analyze the rate of calcification in the liver metastasis from colorectal cancer of different differentiation degrees.
  • Among the 210 cases of liver metastases, 22 patients (10.5%) were found to have calcified liver metastases on CT scan.
  • Two patients with calcified liver metastasis received lumpectomy and developed calcification in recurrent tumors.
  • And the calcification in the newly developed masses was similar to that of their primary counterparts in terms of morphology and distribution.
  • Histopathologically, the primary tumors were well-differentiated adenocarcinoma in 6 cases, moderately-differentiated adenocarcinoma in 10, poorly-differentiated adenocarcinoma in 4 and mucinous adenocarcinoma in 2 among the 22 cases.
  • No statistical correlation was noted between the incidence of calcified liver metastasis and the pathological subtypes and differentiation degrees of the primary colorectal carcinoma.
  • It was concluded that calcified liver metastases may result from colorectal adenocarcinomata of different differentiation degrees or mucinous adenocarcinomata in Chinese population.
  • There is no correlation between calcification of liver metastases and the pathological subtype of the primary colorectal carcinoma in Chinese, which is different from the findings that calcified metastases were associated with colorectal mucinous adenocarcinoma in other ethnic groups.
  • [MeSH-major] Calcinosis / pathology. Colorectal Neoplasms / pathology. Liver / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21181378.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Peng B, Liang L, Chen Z, He Q, Kuang M, Zhou F, Lu M, Huang J: Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma. Hepatogastroenterology; 2006 May-Jun;53(69):409-14
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma.
  • BACKGROUND/AIMS: A tumor vaccine consisting of formalin-fixed hepatocellular carcinoma (HCC) tissue fragments, biodegradable sustained-releasers of granulocyte-macrophage-colony stimulating factor (GM-CSF) and interleukin-2 (IL-2), and an adjuvant was developed.
  • Primary endpoint was time to first recurrence and recurrent rates were analyzed.
  • The recurrent rate was significantly better in the tumor vaccine group (1 year, 12.6%; 2 years, 35.9%; 3 years, 54%) than in the control group (1 year, 31.6%; 2 years, 61.3%; 3 years, 72.1%; P = 0.037).
  • 23/32 patients developed a DTH response against the fragments of HCC and DTH-response-positive patients had a lower recurrent rate than DTH-response-negative patients (7/23 vs. 5/9).
  • [MeSH-major] Cancer Vaccines. Carcinoma, Hepatocellular / prevention & control. Liver Neoplasms / prevention & control. Liver Neoplasms, Experimental / prevention & control. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Cell Line, Tumor. Hepatectomy. Humans. Male. Mice. Mice, Inbred C57BL. Middle Aged. Neoplasm Metastasis / prevention & control. Neoplasm Transplantation. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16795983.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


19. Kehoe SM, Zivanovic O, Ferguson SE, Barakat RR, Soslow RA: Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer. Gynecol Oncol; 2010 May;117(2):229-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer.
  • OBJECTIVE: Patients with advanced or recurrent endometrial cancer often have distant metastases found within the lymph nodes, liver, and/or lung.
  • However, there have been reported cases of primary endometrial cancer with metastasis to the bone.
  • The objective of this study was to describe the clinical and pathologic features of endometrial cancer metastatic to bone.
  • METHODS: A retrospective chart review of our clinical and pathology database was performed to identify women diagnosed with endometrial cancer metastatic to the bone between 1990 and 2007.
  • RESULTS: Twenty-one patients with endometrial cancer metastatic to the bone were identified; in 12 patients (57%), the diagnosis was confirmed by a bone biopsy.
  • The median age of diagnosis of primary endometrial cancer was 60 years (range, 32-84).
  • The overall survival of those patients with bone metastases at primary diagnosis was 17 months (95% CI: 2-32) compared to 32 months (95% CI: 14-49) for those with a recurrent bone metastasis.
  • CONCLUSION: Although a rare event, endometrial cancer can metastasize to the bone.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20199802.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA: High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer; 2008 Jul;47(7):591-603
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss.
  • To evaluate the molecular events underlying carcinoid tumorigenesis, we used high-resolution arrays of single nucleotide polymorphisms to study chromosomal gains and losses in 24 primary and metastatic small bowel carcinoid tumors derived from 18 patients.
  • One focal region of recurrent gain on 14q mapped to the locus of the gene encoding the antiapoptotic protein DAD1, and immunohistochemical staining confirmed DAD1 protein expression in tumor samples.
  • [MeSH-major] Chromosome Aberrations. Intestinal Neoplasms / genetics. Intestine, Small. Liver Neoplasms / genetics. Malignant Carcinoid Syndrome / genetics. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adult. Aged. Apoptosis Regulatory Proteins / genetics. Apoptosis Regulatory Proteins / metabolism. Chromosomes, Human, Pair 9 / genetics. Female. Humans. Immunoenzyme Techniques. Male. Membrane Proteins / genetics. Membrane Proteins / metabolism. Microsatellite Repeats. Middle Aged. Polymorphism, Single Nucleotide / genetics. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18383209.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DAD1 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


21. Katsumata K, Mori Y, Hisada M, Ishizaki T, Suzuki S, Wada T, Tsuchida A, Aoki T: [CR of rectal cancer and synchronous liver and lung metastases obtained with TS-1 plus CPT-11 combination therapy--case report]. Gan To Kagaku Ryoho; 2007 Jan;34(1):113-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CR of rectal cancer and synchronous liver and lung metastases obtained with TS-1 plus CPT-11 combination therapy--case report].
  • The patient was a 44-year-old male in whom low anterior resection of the rectum, partial pneumonectomy, and liver biopsy were performed because of suspicion of synchronous liver and pulmonary metastases of rectal cancer which caused familial adenomatous polyposis.
  • Because anticancer drug sensitivity testing by the HDRA method performed on tissue collected from the cancer immediately postoperatively revealed sensitivity to 5-FU and CPT-11, and measurement of nucleic acid metabolizing enzymes showed a high level of DPD, a 5-FU metabolizing enzyme, combination therapy with TS-1 and CPT-11 was started.
  • Thoracic and abdominal CT was performed after 4 courses, but no recurrent foci were detected in the residual lung tissue, and all of the metastatic liver foci had resolved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Neoplasms, Multiple Primary / drug therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenomatous Polyposis Coli / pathology. Adult. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Diabetes Complications / complications. Diabetes Mellitus, Type 2 / complications. Drug Administration Schedule. Drug Combinations. Humans. Male. Oxonic Acid / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220684.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


22. Lee YK, Park NH, Kim JW, Song YS, Kang SB, Lee HP: Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer; 2008 Jul-Aug;18(4):642-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of recurrence in adult-type granulosa cell tumor.
  • The goal of this study is to evaluate clinical findings, prognostic factors, and recurrent features of GCT in Korean patients.
  • There were 35 cases showing adult-type GCT, which were available for evaluation.
  • The median time to relapse was 75 months (range, 55-137 months), and the liver was the most common extra-pelvic metastatic site followed by the intestine.
  • Active management including complete tumorectomy is the most important treatment modality in both primary surgeries and recurrent cases.
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Metastasis. Prognosis. Recurrence. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868338.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Yan K, Wang YB, Chen MH, Gao W, Yang W, Dai Y, Yin SS: [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors]. Zhonghua Yi Xue Za Zhi; 2005 Aug 31;85(33):2322-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors].
  • OBJECTIVE: To investigate the prognostic factors affecting outcome in Radiofrequency (RF) ablation of primary hepatic tumors by univariate and multivariate analyses, and to assess the therapeutic efficacy of Radio-frequency ablation.
  • METHODS: A total of 172 patients with primary hepatic tumors underwent RF treatment in our department between 1999 and 2004.
  • For 116 patients who underwent RF when first diagnosis, the survival rates in patients with different tumor stage (UICC standard of hepatocellular carcinoma) at half a year, 1 year, 2 year and 3 year were estimated as follows: 96.7%, 92.3%, 81.6% and 65.3% in 33 patients of stage I-II; 91.2%, 76.3%, 56.6% and 51.4% in 83 patients of stage III-IV; There was significant difference in survival rates between patients of stage I-II and patients of stage III-IV.
  • For 56 patients suffered from recurrent hepatic tumors, the survival rates at half a year, 1 year, 2 year and 3 year were 88.5%, 70.2%, 41.4% and 24.5%, being similar to those of stage III-IV.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321224.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


24. Abouljoud M, Yoshida A, Kim D, Jerius J, Arenas J, Raoufi M, Brown K, Moonka D: Transjugular intrahepatic portosystemic shunts for refractory ascites after liver transplantation. Transplant Proc; 2005 Mar;37(2):1248-50
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transjugular intrahepatic portosystemic shunts for refractory ascites after liver transplantation.
  • PURPOSE: To study the efficacy of transjugular intrahepatic portosystemic shunts (TIPS) in the management of refractory ascites after liver transplantation.
  • PATIENTS AND METHODS: Between January 1995 and December 2003, 309 primary adult liver transplants were performed.
  • Hepatitis C was the primary diagnosis in 7 patients and primary biliary cirrhosis in 1.
  • Two patients required retransplantation for recurrent hepatitis C.
  • There were 3 deaths: liver failure (1), organ failure after retransplantation (1), and lung cancer 5 months after TIPS (1).
  • CONCLUSIONS: The TIPS device can be used safely and effectively to control refractory ascites after liver transplantation.
  • [MeSH-major] Ascites / surgery. Hepatitis C / surgery. Liver Transplantation. Portasystemic Shunt, Transjugular Intrahepatic. Postoperative Complications / surgery
  • [MeSH-minor] Adult. Blood Pressure. Female. Follow-Up Studies. Hepatic Veins. Humans. Male. Middle Aged. Portal Vein. Retrospective Studies. Time Factors. Varicose Veins / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848685.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM: Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother; 2009 Jan;58(1):61-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial.
  • PURPOSE: Metastatic disease is a major cause of mortality in colorectal cancer patients.
  • Even after complete resection of isolated liver metastases, recurrence develops in the majority of patients.
  • Therefore, development of strategies to prevent recurrent liver metastases is of major clinical importance.
  • The present prospectively randomised phase III trial investigates the efficiency of active specific immunotherapy (ASI) after liver resection for hepatic metastases of colorectal cancer.
  • METHODS: Patients with histologically confirmed liver metastases from colorectal cancer were randomised to the vaccination or control group.
  • After complete resection of liver metastases, patients randomised to the vaccination group received six doses of Newcastle disease virus (NDV) infected autologous tumour cell vaccine (ATV-NDV).
  • The primary end-point was overall survival, secondary end-points were disease-free survival and metastases-free survival.
  • In the total patient group, no differences in the primary and secondary end-points were detected.
  • Most interestingly, subgroup analysis revealed a significant advantage for vaccinated colon cancer patients with respect to overall survival [hazard ratio: 3.3; 95%, confidence interval (CI): 1.0-10.4; P = 0.042] and metastases-free survival (hazard ratio: 2.7; 95%, CI: 1.0-7.4; P = 0.047) in the intention-to-treat analysis.
  • CONCLUSION: Active specific immunotherapy in unselected colorectal cancer patients was not effective for prevention of recurrent metastatic disease.
  • However, in colon cancer patients, ASI with ATV-NDV appears to be beneficial prolonging overall and metastases-free survival.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Cancer Vaccines / immunology. Colorectal Neoplasms / drug therapy. Hepatectomy. Immunotherapy, Active. Liver Neoplasms / drug therapy. Newcastle disease virus
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18488223.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines
  •  go-up   go-down


26. Chang AY, Lopes G, Hsin KW, Lim R, Fong FK, Wong J: Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study. Clin Colorectal Cancer; 2007 Sep;6(9):646-51
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
  • BACKGROUND: Second-line treatment of relapsed or metastatic colorectal cancer (CRC) after failure of treatment with a fluoropyrimidine is composed of oxaliplatin in combination with a fluoropyrimidine or an irinotecan-containing regimen.
  • PATIENTS AND METHODS: A 2-stage phase II trial was conducted to assess the efficacy (the primary endpoint was response rate) and safety of a regimen consisting of 5-FU 400 mg/m(2) as an intravenous bolus at the middle of a 60-minute infusion of leucovorin 100 mg/m(2), followed by gemcitabine 800 mg/m(2) over 80 minutes, and cisplatin 20 mg/m(2) over 15 minutes.
  • Twelve patients had colon cancer and 7 had rectal cancer.
  • Sites of metastasis were as follows: liver (n = 10), lung (n = 8), skin (n = 1), and non-regional lymph nodes (n = 1).
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / drug therapy. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17945037.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Yong TL, Bohmer R, Pande GK, Birks SE, Loh DC, Hewitt PM: Liver resection: a regional hospital experience. ANZ J Surg; 2010 Oct;80(10):710-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection: a regional hospital experience.
  • BACKGROUND: Liver resection is a significant operation usually limited to large metropolitan hospitals.
  • Liver resections were first performed at the Launceston General Hospital (LGH), a regional centre (bed capacity 280), in May 2000.
  • This is a summary of liver resection at LGH.
  • METHODS: Data of liver resections performed between May 2000 and March 2008 at LGH were collected retro-prospectively and reviewed with attention to patient survival, post-operative complications and mortality.
  • RESULTS: There were 102 consecutive liver resections during the study period.
  • Six patients had metastases from primaries other than colorectal cancer.
  • There were 13 resections for primary liver malignancy, 2 from invasion by gallbladder carcinoma, 1 for contiguous invasion by gastric cancer and 19 were for benign conditions.
  • At the end of the study period, 51 cancer patients were still alive (14 with disease recurrences) and 30 have died (23 from recurrent diseases).
  • Patients operated for colorectal cancer metastases achieved a 44% 5-year survival rate (median survival = 46 months).
  • Patients with hepatocellular carcinoma had 3-year survival rate of 15% (median survival = 24 months).
  • CONCLUSION: Resection provides the best hope of cure for patients with primary or secondary hepatic malignancy.
  • With adequate expertise, liver resections can be performed safely in a regional hospital.
  • [MeSH-major] Hepatectomy / statistics & numerical data. Liver Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Female. Hospitals, General. Humans. Male. Middle Aged. Postoperative Complications. Prospective Studies. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. ANZ Journal of Surgery © 2010 Royal Australasian College of Surgeons.
  • [ErratumIn] ANZ J Surg. 2011 Jan;81(1-2):107
  • (PMID = 21040331.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


28. Abraham SC, Poterucha JJ, Rosen CB, Demetris AJ, Krasinskas AM: Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. Am J Surg Pathol; 2008 Jul;32(7):965-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests.
  • The utility of protocol liver allograft biopsies remains controversial, particularly in patients with normal liver function tests (LFTs).
  • However, histologic evaluation of these biopsies provides an opportunity to examine the types and severity of liver diseases that can occur in livers with normal clinical and biochemical function.
  • We studied 165 protocol allograft biopsies taken from 100 liver transplant patients at the time of normal LFTs and normal clinical function at 3 to 8 months (n=36), 1 year (n=52), 2 to 3 years (n=54), and 4 to 5 years (n=23).
  • Biopsies were classified as normal, minimal changes (eg, nonaggressive portal or lobular mononuclear inflammation, steatosis <10%), fatty liver disease, recurrent primary liver disease, and transplant-related disease (portal-based rejection or central venulitis, an inflammatory pattern that encompasses perivenular hepatocyte dropout, mononuclear inflammation, pigment-laden macrophages, and variable zone 3 fibrosis).
  • Forty-four (27%) showed histologic abnormalities that included fatty liver disease (n=19, nonalcoholic in 18 cases; 13 with mild steatosis, 6 with moderate steatosis, 7 with grade 1/3 steatohepatitic activity, and 2 with stage 1/4 steatohepatitic fibrosis), recurrent primary biliary cirrhosis (n=9; all stage 1/4), recurrent hepatitis C infection (n=6; grade 0/4 in 1, grade 1/4 in 5, stage 0/4 in 4, stage 1/4 in 1, and stage 2/4 in 1), recurrent sarcoidosis (n=1), Ito cell hyperplasia (n=4; marked in 2 and mild in 2), central venulitis (n=10; 5 with mild zone 3 fibrosis or central vein obliteration and 1 with central-portal bridging fibrosis), and mild acute portal rejection (n=2).
  • These most commonly include fatty liver disease, low-grade/low-stage recurrent hepatitis C and primary biliary cirrhosis, and central venulitis (including some cases with subsequent fibrosis progression).
  • The data support performance of protocol biopsies to assess allograft status, and provide insight into the types and severity of liver diseases that can smolder in transplanted (and by extension, probably also in native) livers with apparent normal function.
  • [MeSH-major] Liver Diseases / diagnosis. Liver Transplantation / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Child. Child, Preschool. Clinical Protocols. Fatty Liver / diagnosis. Fatty Liver / physiopathology. Female. Hepatitis C, Chronic / diagnosis. Hepatitis C, Chronic / physiopathology. Humans. Infant. Liver Cirrhosis, Biliary / diagnosis. Liver Cirrhosis, Biliary / physiopathology. Liver Function Tests. Male. Middle Aged. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460980.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB: Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation; 2006 Dec 27;82(12):1703-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma.
  • BACKGROUND: Sixty-five patients with unresectable hilar cholangiocarcinoma (CCA) have undergone orthotopic liver transplantation (OLT) after neoadjuvant chemoradiotherapy per a clinical care protocol developed in 1993.
  • Mean time to recurrence was 29 months, and eight patients had died from recurrent disease.
  • Predictors of recurrence were older age, pretransplant cancer antigen (CA) 19-9 >100 U/ml, prior cholecystectomy, mass on cross-sectional imaging, residual tumor in explant >2 cm, tumor grade and perineural invasion in explant.
  • Underlying primary sclerosing cholangitis, percutaneous biliary intubation, gender, and other time points for CA 19-9 were not associated with recurrence.
  • Prolonged staging-to-OLT intervals for patients transplanted after implementation of model for end-stage liver disease (MELD) showed a trend toward increased recurrence.
  • CONCLUSIONS: Older patients and those with high CA-19.9 levels, and larger tumors are more likely to develop recurrent disease.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. CA-19-9 Antigen / blood. Cholangiocarcinoma / therapy. Liver Transplantation. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Risk Factors


30. Wong LL, Limm W, Cheung A, Noguchi H: Liver transplant in Hawaii: the survival of a small centre. Clin Transplant; 2006 Jan-Feb;20(1):55-61
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplant in Hawaii: the survival of a small centre.
  • Although many report the importance of case volume in complex cases, liver transplantation (LT) can be carried out successfully in a small centre.
  • Indications for LT were primarily hepatitis C (n = 49) and hepatitis B (n = 13) and 22 patients (25%) had hepatocellular cancer (HCC) on explanted liver.
  • There was no primary graft nonfunction, one retransplant for recurrent hepatitis C and two late hepatic artery thromboses, which did not require a retransplant.
  • Of the 22 patients with HCC, 18 are alive, two died from recurrent disease (253 and 1428 d post-LT, respectively), one died because of a ruptured hepatic artery aneurysm (151 d) and one from complications caused by noncompliance (723 d).
  • During this time period, 142 liver resections, 77 pancreatic resections and 43 splenorenal shunts were performed by this group of surgeons.
  • [MeSH-major] Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Female. Hawaii. Hepatitis B / surgery. Hepatitis C / surgery. Humans. Male. Middle Aged. Quality of Health Care. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556154.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


31. Garioud A, Seksik P, Chrétien Y, Corphechot C, Poupon R, Poupon RE, Chazouillères O: Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur J Gastroenterol Hepatol; 2010 Jul;22(7):842-7
Genetic Alliance. consumer health - Primary sclerosing cholangitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
  • BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) is a rare disease, and large-scale report of PSC in France is lacking.
  • At entry, 11 patients had a diagnosis of hepatobiliary or colon malignancy (cholangiocarcinoma: n = 5, hepatocellular carcinoma: n = 2, gallbladder carcinoma: n = 1 and colorectal cancer: n = 4).
  • RESULTS: During follow-up [3.9 (0.1-7.2) years], colorectal cancer was diagnosed in four patients and biliary carcinoma in two (incidences: 0.76 and 0.38 for 100 patient-years, respectively).
  • Main causes of death (n = 10) were cancer (n = 5, including three colorectal cancers and two cholangiocarcinoma) or liver failure (n = 4).
  • Indications for transplantation (n = 25) were end-stage liver disease (n = 16), biliary cancer (known or suspected) (n = 5), recurrent acute cholangitis (n = 3) or pruritus (n = 1).
  • [MeSH-major] Cholangitis, Sclerosing / diagnosis. Cholangitis, Sclerosing / mortality. Liver Failure / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic / drug effects. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / drug therapy. Cohort Studies. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Female. France / epidemiology. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / drug therapy. Humans. Incidence. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Transplantation. Male. Middle Aged. Prognosis. Prospective Studies. Treatment Outcome. Ursodeoxycholic Acid / therapeutic use. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779305.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


32. Kinoshita S, Hirano A, Komine K, Kobayashi S, Kyoda S, Takeyama H, Uchida K, Morikawa T, Nagase J, Sakamoto G: Primary small-cell neuroendocrine carcinoma of the breast: report of a case. Surg Today; 2008;38(8):734-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small-cell neuroendocrine carcinoma of the breast: report of a case.
  • Primary small-cell neuroendocrine carcinoma of the breast is a rare and aggressive neoplasm without an established treatment protocol because so few cases have been described.
  • We report a case of primary small-cell neuroendocrine carcinoma in a 31-year-old woman.
  • The patient came to our hospital 10 days after consulting another clinic, where a diagnosis of locally advanced breast cancer suitable for neoadjuvant chemotherapy had been made.
  • Core needle biopsy under ultrasonographic guidance revealed invasive carcinoma.
  • Definitive histopathological examination revealed primary small-cell neuroendocrine carcinoma.
  • Local and mediastinal recurrence with multiple liver metastases developed only 5 weeks after surgery.
  • Cisplatin plus irinotecan combination chemotherapy was started; however, the patient died of aggressive recurrent tumor progression 6 months after surgery, in spite of the transient tumor regression achieved by chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):117-21 [14750249.001]
  • [Cites] Pathol Int. 1998 Sep;48(9):744-8 [9778114.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):64-6 [17270668.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):30-8 [17270663.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Dec;23 (4):691-6 [15743041.001]
  • [Cites] Am J Clin Oncol. 1995 Apr;18(2):133-8 [7534975.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):121-5 [6303551.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1231-8 [10976697.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 May;17(3):201-2 [15901010.001]
  • [Cites] Histopathology. 2001 Mar;38(3):277-8 [11260311.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4 Suppl):1341-4 [9990271.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):296-8 [10656743.001]
  • [Cites] Oncol Rep. 2004 Apr;11(4):825-31 [15010880.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2004 Aug 10;115(2):231-3 [15262362.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Hum Pathol. 2001 Jul;32(7):753-7 [11486176.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;404(2):213-21 [6091325.001]
  • [Cites] Breast. 2004 Apr;13(2):149-51 [15019697.001]
  • [Cites] J Clin Pathol. 2006 Aug;59(8):888 [16873572.001]
  • [Cites] Pathol Int. 2000 Nov;50(11):914-8 [11107070.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(1):103-8 [1311484.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):775-8 [15976350.001]
  • (PMID = 18668318.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


33. Kim HO, Hwang SI, Hong HP, Yoo CH: Radiofrequency ablation for metachronous hepatic metastases from gastric cancer. Surg Laparosc Endosc Percutan Tech; 2009 Jun;19(3):208-12
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for metachronous hepatic metastases from gastric cancer.
  • Between January 2000 and February 2008, we retrospectively reviewed 7 cases for which RFA was performed for treating metachronous hepatic metastases after resection of the primary gastric adenocarcinoma.
  • A second RFA was performed for a single recurrent hepatic metastasis in 1 patient and this patient survived more than 3 years without recurrence until the time of this study.
  • Combination therapy such as systemic chemotherapy or hepatic arterial infusion chemotherapy adjuvant to RFA would more reasonable for treating hepatic metastases from gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Catheter Ablation / methods. Hepatectomy / methods. Liver Neoplasms / surgery. Neoplasms, Second Primary / surgery. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Female. Follow-Up Studies. Gastrectomy / methods. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542847.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC: Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):486-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
  • PURPOSE: We performed a Phase I dose-escalation study to explore the feasibility and safety of treating primary and metastatic liver tumors with single-fraction stereotactic body radiotherapy (SBRT).
  • Nineteen patients had hepatic metastases, 5 had intrahepatic cholangiocarcinomas, and 2 had recurrent hepatocellular carcinomas.
  • Fifteen patients have died: 11 treated for liver metastases and 4 with primary liver tumors died.
  • CONCLUSIONS: It is feasible and safe to deliver single-fraction, high-dose SBRT to primary or metastatic liver malignancies measuring ≤5 cm.
  • Moreover, single-fraction SBRT for liver lesions demonstrated promising local tumor control with minimal acute and long-term toxicity.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Duodenal Ulcer / etiology. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Radiation Injuries / pathology. Radiotherapy Dosage. Survival Analysis. Treatment Failure. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20350791.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Li XW, Gong SJ, Song WH, Zhu JJ, Pan CH, Wu MC, Xu AM: Undifferentiated liver embryonal sarcoma in adults: a report of four cases and literature review. World J Gastroenterol; 2010 Oct 7;16(37):4725-32
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated liver embryonal sarcoma in adults: a report of four cases and literature review.
  • AIM: To evaluate the undifferentiated embryonal sarcoma of liver (UESL) in adults in order to improve its diagnosis and treatment.
  • METHODS: Four primary and one recurrent cases of UESL were clinicopathologically evaluated and immunohistochemically investigated with a panel of antibodies using the EnVision+ system.
  • [MeSH-major] Liver Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Differentiation. Child. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Embryonal Sarcoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Dev Pathol. 2001 Sep-Oct;4(5):482-9 [11779051.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(5):536-44 [18836810.001]
  • [Cites] J Pediatr Surg. 2002 Oct;37(10):1419-23 [12378446.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):246-52 [12673559.001]
  • [Cites] Endoscopy. 1977 May;8(2):108-10 [140795.001]
  • [Cites] Gastroenterology. 1978 Jan;74(1):121-3 [72700.001]
  • [Cites] Cancer. 1978 Jul;42(1):336-48 [208754.001]
  • [Cites] Cancer. 1983 Apr 15;51(8):1510-7 [6681727.001]
  • [Cites] Histopathology. 1983 Jan;7(1):113-21 [6840705.001]
  • [Cites] Pediatr Pathol. 1983 Jul-Sep;1(3):281-90 [6687281.001]
  • [Cites] Gut. 1987 Jun;28(6):668-74 [3623214.001]
  • [Cites] Am J Surg Pathol. 1991 Jan;15(1):1-16 [1702267.001]
  • [Cites] Hepatogastroenterology. 1992 Aug;39(4):319-21 [1427575.001]
  • [Cites] Ann Clin Lab Sci. 1994 Nov-Dec;24(6):495-500 [7847778.001]
  • [Cites] Curr Top Pathol. 1995;89:261-72 [7882713.001]
  • [Cites] Am Surg. 1996 Nov;62(11):901-6 [8895710.001]
  • [Cites] Radiology. 1997 Jun;203(3):779-83 [9169704.001]
  • [Cites] J Hepatol. 2005 Mar;42(3):424-9 [15710230.001]
  • [Cites] Arch Pathol Lab Med. 2006 Feb;130(2):e24-6 [16454576.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):193-7 [16785789.001]
  • [Cites] World J Gastroenterol. 2008 Dec 21;14(47):7267-70 [19084947.001]
  • [Cites] J Dig Dis. 2009 Nov;10(4):305-9 [19906110.001]
  • [Cites] Chin Med J (Engl). 2010 Jan 20;123(2):250-2 [20137381.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):195-8 [19809302.001]
  • [Cites] Ultrastruct Pathol. 2006 Nov-Dec;30(6):403-8 [17182431.001]
  • [Cites] J Gastrointest Surg. 2007 Jan;11(1):73-5 [17390190.001]
  • [Cites] Histopathology. 2007 Aug;51(2):195-203 [17573940.001]
  • [Cites] Cancer. 2008 May 15;112(10):2274-82 [18361435.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):252-7 [11815984.001]
  • (PMID = 20872975.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2951525
  •  go-up   go-down


36. Shoji F, Kawano D, Ikegami T, Soejima Y, Taketomi A, Yano T, Maehara Y: Surgical resection of pulmonary malignant tumors after living donor liver transplantation. Ann Thorac Surg; 2009 Jul;88(1):206-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of pulmonary malignant tumors after living donor liver transplantation.
  • BACKGROUND: The aim of this study is to report on patients who developed tumor recurrence of the lung or de novo pulmonary malignancies after living donor liver transplantation (LDLT) and to show the benefit of a surgical resection for these pulmonary malignant tumors.
  • The frequency of pulmonary recurrence was 9.4% (9 of 96 patients) and that of pulmonary de novo malignancies including 2 primary lung cancer and 1 mucosa-associated lymphoid tissue (MALT) lymphoma, was 1.2% (3 of 246 patients).
  • Four of 9 recurrent patients could undergo surgical resections and the survival range in patients who received surgery was 17 to 56 months with a mean of 36 months after LDLT; on the other hand, the survival range in patients that could not undergo a surgical resection was 4 to 26 months with a mean of 18 months.
  • [MeSH-major] Liver Failure / surgery. Liver Transplantation / methods. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adult. Age Factors. Aged. Cohort Studies. Female. Follow-Up Studies. Graft Survival. Humans. Kaplan-Meier Estimate. Living Donors. Male. Middle Aged. Neoplasm Staging. Probability. Retrospective Studies. Risk Assessment. Sex Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19559227.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


37. Hwang SE, Yang DH, Kim CY: Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer. World J Surg; 2009 Jul;33(7):1468-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer.
  • BACKGROUND: This study was done to evaluate the prognostic factors that may affect the survival of patients with recurrent hepatic metastasis after curative resection of gastric cancer.
  • METHODS: We reviewed the medical records of 73 patients with recurrent hepatic metastasis after surgical treatment of gastric cancer from January 1995 to December 2005.
  • Prognostic factors were classified into three groups: primary tumor factors, recurrent hepatic factors, and treatment factors.
  • The median survival rate after diagnosis of recurrent hepatic metastasis was 5 months (95% CI 3.5-6.5 months).
  • Univariate analysis showed that the favorable prognostic factors were stage I and II among the primary tumor factors, no extrahepatic metastasis and unilobar distribution among the recurrent hepatic factors, and radiofrequency ablation (RFA) +/- chemotherapy among the treatment factors when operative treatment had been excluded.
  • CONCLUSIONS: Improvement in the survival rate can be expected with RFA +/- chemotherapy for patients with recurrent gastric cancer in the liver without extrahepatic metastasis.
  • [MeSH-major] Liver Neoplasms / mortality. Liver Neoplasms / secondary. Neoplasm Recurrence, Local / mortality. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Cohort Studies. Confidence Intervals. Disease-Free Survival. Female. Gastrectomy / methods. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vasc Interv Radiol. 2005 Dec;16(12):1747-51 [16371545.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2445-8 [8640691.001]
  • [Cites] Radiology. 2003 Feb;226(2):441-51 [12563138.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1175-8 [7953354.001]
  • [Cites] J Surg Oncol. 2007 Jun 1;95(7):534-9 [17219383.001]
  • [Cites] J Surg Oncol. 1987 Dec;36(4):239-42 [3695528.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):624-30 [12174368.001]
  • [Cites] World J Surg. 1987 Aug;11(4):418-25 [3630186.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Jun;19(2):211-7 [10965821.001]
  • [Cites] World J Surg. 1997 Feb;21(2):186-89; discussion 190 [8995076.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):490-3 [9068476.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):86-91 [11753046.001]
  • [Cites] Surgery. 2003 May;133(5):507-11 [12773978.001]
  • [Cites] Cancer. 1985 May 15;55(10):2498-505 [3986746.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):356-9 [6158880.001]
  • [Cites] Br J Surg. 1992 Mar;79(3):245-7 [1555092.001]
  • (PMID = 19381718.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Kandil D, Leiman G, Allegretta M, Evans M: Glypican-3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry study. Cancer; 2009 Aug 25;117(4):271-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry study.
  • Fine-needle aspiration (FNA) is critical in documenting recurrent/metastatic disease in established cases.
  • In liver FNA, the distinction between hepatocellular carcinoma (HCC) and MM is a frequent challenge.
  • Serum GPC3 was shown to be expressed in 40% of primary melanomas (PMs), but to the authors' knowledge no tissue studies to date have assessed GPC3 expression in MM.
  • In this study, GPC3 protein expression was investigated in FNAs from MM, and in corresponding histologic sections from the primary tumors.
  • FNA and core biopsy specimens from HCCs and benign liver were used as positive and negative controls.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Cancer Society
  • (PMID = 19517479.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glypicans
  •  go-up   go-down


39. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S: Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery; 2007 Mar;141(3):330-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.
  • BACKGROUND: Tumor recurrence remains the major cause of death after curative resection for hepatocellular carcinoma (HCC).
  • METHODS: From July 1992 to July 2004, 193 consecutive patients who underwent hepatic resection as primary therapy with curative intent for HCC were included in this single-center analysis.
  • After a median follow-up time of 34 months, 98 patients (51%) experienced recurrent cancer; initial tumor recurrence was confined to the liver in 86 patients (88%).
  • Of the 98 patients who had tumor recurrence, 53 patients (54%) underwent additional therapy (ablation, 31 patients; re-resection, 11 patients; transarterial chemoembolization, 8 patients; liver transplantation, 3 patients) with improvement in survival.
  • Identification of risk factors, close follow-up evaluation, and early detection are mandatory because recurrences that are confined to the liver may be amenable to treatment with an additional survival benefit.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / epidemiology. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349844.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Welter S, Jacobs J, Krbek T, Krebs B, Stamatis G: Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg; 2007 Jul;84(1):203-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after repeated resection of pulmonary metastases from colorectal cancer.
  • BACKGROUND: The purpose of this study was to evaluate the outcome of patients undergoing repeated resection of pulmonary metastases from colorectal cancer and specify factors promising long-term survival.
  • METHODS: From January 1993 to December 2003, 175 patients were diagnosed and resected for pulmonary metastases of colorectal cancer.
  • Follow-up information was collected for 169 patients, and 33 (19.5%) had had recurrent metastasectomies up to three times.
  • After reoperation, age, sex, primary tumor stage, preoperative carcinoembryonic antigen, disease-free interval, prior resection of liver metastases, and lymph node involvement were not found to be of prognostic importance.
  • CONCLUSIONS: Repeated resection of pulmonary metastases secondary to colorectal cancer is safe and can provide long-term survival for highly selected patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Prognosis. Reoperation. Retrospective Studies

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17588413.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


41. Fan WJ, Zhang L, Ouyang YS: [Evaluation of the effect of transcatheter arterial chemoembolization in treatment of primary hepatocellular carcinoma with magnetic resonance diffusion-weighted imaging: 4-6-week follow-up of 25 cases]. Zhonghua Yi Xue Za Zhi; 2008 Sep 16;88(35):2474-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the effect of transcatheter arterial chemoembolization in treatment of primary hepatocellular carcinoma with magnetic resonance diffusion-weighted imaging: 4-6-week follow-up of 25 cases].
  • OBJECTIVE: To investigate the value of MR diffusion-weighted imaging (DWI) in evaluating the efficacy of treatment of primary hepatocellular carcinoma (HCC) by transcatheter arterial chemoembolization (TACE).
  • The differences in the mean apparent diffusion coefficient (ADC) value of the remaining tumor, coagulation tumor necrotic tissue, and post-operative recurrent tumor tissue were compared and analyzed.
  • RESULTS: When the b value was 1000 s/mm(2), the ADC values of the liver tissue, tumor tissue before first TACE, remaining tumor, coagulation tumor necrotic tissue, and post-operative recurrent tumor were 1.25 +/- 0.07, 1.02 +/- 0.19, 1.06 +/- 0.14, 1.68 +/- 0.32, and 1.28 +/- 0.07 mmxs(-1)x10(-3) respectively.
  • The ADC values of the tumor tissue before the first TACE was the lowest, and the ADC value of the post-operative recurrent tumor was significantly higher than that of the tumor tissue before the first TACE (P < 0.05).
  • The ADC value of the remaining tumor tissue was between that of the post-operative recurrent tumor and that of the tumor tissue before the first TACE, however, without significant differences among them.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Diffusion Magnetic Resonance Imaging. Liver Neoplasms / pathology. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080627.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Park SS, Kim CS, Mok YJ, Kim SJ, Kim HI: Gastric cancer confined to the muscularis propria: a possible candidate for laparoscopic surgery or adjuvant therapy. Scand J Gastroenterol; 2005 Apr;40(4):450-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer confined to the muscularis propria: a possible candidate for laparoscopic surgery or adjuvant therapy.
  • OBJECTIVE: Gastric cancer confined to the muscularis propria (mp) has a favorable prognosis, but still belongs to the advanced category.
  • Many oncologists have difficulties in selecting treatment modalities owing to the confused situation of mp cancer.
  • To clarify the therapeutic strategy, the clinicopathological characteristics were investigated, and the risk factors, of this intermediate-stage gastric cancer, evaluated.
  • MATERIAL AND METHODS: A total of 155 patients who underwent curative resection for primary gastric cancer between 1993 and 2001 were diagnosed with mp cancer.
  • The patients were divided into recurrent and non-recurrent groups and analyzed clinicopathologically.
  • A multivariate analysis disclosed only lymphatic metastasis as an independent risk factor for recurrence of mp cancer.
  • Hematogenous metastasis accounted for 37% of the recurrent patterns, and the liver (83.3%) was the most common organ.
  • The 5-year survival rate of all mp cancer patients was 80.9%, but that of patients with recurrent disease was 19.2%.
  • CONCLUSIONS: Lymph node metastasis is the only significant risk factor of mp cancer.
  • On the other hand, patients with mp cancer without lymph node involvement have an excellent prognosis and could be candidates for laparoscopic gastric surgery.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Gastrectomy. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028440.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


43. Chintamani, Singhal V, Bansal A, Bhatnagar D, Saxena S: Isolated colostomy site recurrence in rectal cancer-two cases with review of literature. World J Surg Oncol; 2007;5:52
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated colostomy site recurrence in rectal cancer-two cases with review of literature.
  • Various etiological factors like adenoma-cancer sequence, bile acids, recurrent and persistent physical damage at the colostomy site by faecal matter due to associated stomal stenosis have been considered responsible.
  • Two such cases are being reported and in both cases there was no evidence of any local recurrence in the pelvis or liver and distant metastasis.
  • CASE PRESENTATION: First case was a 30-year-old male that had reported with large bowel obstruction due to an obstructing ulcero-proliferative growth (poorly differentiated adenocarcinoma) at the colostomy site after abdomino-perineal resection, performed for low rectal cancer six years previously.
  • Four years later he presented with massive malignant ascites, cachexia and multiple liver metastasis and succumbed to his disease.
  • CONCLUSIONS: Colostomy site/scar recurrence of rectal carcinoma is rare and could be due to various etiological factors, although the exact causative mechanism is not known.
  • [MeSH-major] Adenocarcinoma / pathology. Colostomy / adverse effects. Neoplasms, Second Primary / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2002;37(5):387-90 [12051539.001]
  • [Cites] J Postgrad Med. 2003 Apr-Jun;49(2):157-8 [12867694.001]
  • [Cites] Gastroenterology. 1958 Jan;34(1):85-98 [13501357.001]
  • [Cites] Cancer. 1974 Jun;33(6):1630-4 [4834157.001]
  • [Cites] Dis Colon Rectum. 1983 Jan;26(1):50-2 [6822162.001]
  • [Cites] Dis Colon Rectum. 1966 Nov-Dec;9(6):441-6 [5926156.001]
  • (PMID = 17567928.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  • [Other-IDs] NLM/ PMC1876234
  • [General-notes] NLM/ Original DateCompleted: 20070730
  •  go-up   go-down


44. Valbuena JR, Levenback C, Mansfield P, Liu J: Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):289-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature.
  • Primary angiosarcomas of the spleen are rare and almost always fatal.
  • The liver is the most common site.
  • We report a case of the 43-year-old woman with a long-standing history of recurrent ovarian carcinoma treated with surgery and multiple courses of radiation therapy and chemotherapy who clinically appeared to have a metastatic ovarian cancer to the spleen and treated with partial resection of stomach and splenectomy.
  • However, histopathologic examination of the specimen showed the tumor to be of a primary angiosarcoma.
  • [MeSH-major] Hemangiosarcoma / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


45. Ji SH, Park YS, Lee J, Lim DH, Park BB, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K: Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer. Jpn J Clin Oncol; 2005 Apr;35(4):214-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
  • BACKGROUND: We evaluated the efficacy and tolerability of a modified biweekly irinotecan, 5-fluorouracil and leucovorin regimen (modified Douillard regimen) as the first-line therapy in patients with advanced colorectal cancer.
  • METHODS: A total of 80 patients (41 male, 39 female) with recurrent or metastatic colorectal cancer were enrolled between April 2001 and December 2003.
  • The primary end-point was response rate, and the secondary end-points were time to progression and toxicity profile.
  • CONCLUSION: We conclude that the modified Douillard regimen may be a practical and more tolerable treatment option in patients with advanced colorectal cancer.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Leukopenia / chemically induced. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15845571.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


46. Karagol H, Saip P, Eralp Y, Topuz S, Berkman S, Ilhan R, Topuz E: Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer. Tumori; 2009 Mar-Apr;95(2):207-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer.
  • AIMS AND BACKGROUND: It has been appreciated for some time that the lack of detection of ovarian cancer at clinical and pathological (second-look laparotomy) evaluation is not synonymous with cure.
  • The goal of this study was to define clinical risk factors for recurrence after complete pathological response to postoperative chemotherapy in patients with epithelial ovarian cancer.
  • The characteristics (age, menopausal status, histological subtype, tumor grade, presence of ascites at diagnosis, type of omentectomy, FIGO stage, and residual tumor volume after primary surgery) of patients with and those without tumor recurrence were compared.
  • At the time of the study analysis, 21 of 57 (37%) patients had recurrent disease.
  • [MeSH-major] Abdominal Neoplasms / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / etiology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Ovariectomy. Risk Assessment. Risk Factors. Treatment Outcome


47. Ma H, Zhang Y, Wang Q, Li Y, He J, Wang H, Sun J, Pan K, Chen M, Xia J: Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther; 2010 Jun 1;9(11):903-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation.
  • Hepatocellular carcinoma (HCC) recurs frequently after minimally invasive therapy.
  • Computed tomography was used to observe the tumor recurrent conditions of patients by every 2 m.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation. Immunotherapy, Adoptive / methods. Killer Cells, Natural / transplantation. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Cell Line, Tumor. Cells, Cultured. Combined Modality Therapy. Cytotoxicity Tests, Immunologic. Cytotoxicity, Immunologic / immunology. Female. Fibronectins / immunology. Hep G2 Cells. Humans. Immunophenotyping. Interferon-gamma / metabolism. Lymphocyte Activation / immunology. Lymphocytes / immunology. Lymphocytes / metabolism. Male. Middle Aged. Recombinant Proteins / immunology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364106.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Fibronectins; 0 / Recombinant Proteins; 0 / retronectin; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


48. Kleespies A, Füessl KE, Seeliger H, Eichhorn ME, Müller MH, Rentsch M, Thasler WE, Angele MK, Kreis ME, Jauch KW: Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis; 2009 Sep;24(9):1097-109
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer.
  • PURPOSE: The benefit of elective primary tumor resection for non-curable stage IV colorectal cancer (CRC) remains largely undefined.
  • Patients with recurrent tumors, resectable metastases, emergency operations, and non-resective surgery were excluded.
  • RESULTS: Patients with colon cancer (CC = 156) and rectal cancer (RC = 77) were comparable with regard to age, sex, comorbidity, American Society of Anesthesiologists score, carcinoembryonic antigen levels, hepatic spread, tumor grade, resection margins, 30-day mortality (CC 5.1%, RC 3.9%) and postoperative chemotherapy. pT4 tumors, carcinomatosis, and non-anatomical resections were more common in colon cancer patients, whereas enterostomies (CC 1.3%, RC 67.5%, p < 0.0001), anastomotic leaks (CC 7.7%, RC 24.2%, p = 0.002), and total surgical complications (CC 19.9%, RC 40.3%, p = 0.001) were more frequent after rectal surgery.
  • Independent determinants of an increased postoperative morbidity were primary rectal cancer, hepatic tumor load >50%, and comorbidity >1 organ.
  • CONCLUSIONS: Palliative resection is associated with a particularly unfavorable outcome in rectal cancer patients presenting with a locally advanced tumor (pT4, expected R2 resection) or an extensive comorbidity, and in all CRC patients who show a hepatic tumor load >50%.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Female. Humans. Liver Neoplasms. Male. Middle Aged. Morbidity. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1646-52 [14668590.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):749-54 [7172942.001]
  • [Cites] J Surg Oncol. 2002 Sep;81(1):3-7 [12210018.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1731-6 [9448628.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Ann Surg Oncol. 2008 Apr;15(4):1099-106 [18181002.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):203-13 [12894013.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):262-5 [15019919.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):954-60 [12464586.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):107-16 [11163503.001]
  • [Cites] Int J Colorectal Dis. 2009 Jun;24(6):699-709 [19221767.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):846-50 [1698594.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1142-55 [10971419.001]
  • [Cites] Am J Surg. 2000 Dec;180(6):407-11; discussion 412 [11182388.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):156-60 [9075749.001]
  • [Cites] Z Gastroenterol. 2002 Aug;40(8):551-6 [12297977.001]
  • [Cites] Int J Colorectal Dis. 2004 May;19(3):197-202 [14618348.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):523-8 [16705728.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] Dis Colon Rectum. 1988 Nov;31(11):842-7 [2460299.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1116-20 [8869321.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Arch Surg. 1987 Jun;122(6):640-3 [2437881.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):163-4 [11167862.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34 [17145522.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):580-5 [10805846.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1425-9 [9407979.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Surg Endosc. 2008 Aug;22(8):1818-25 [18095024.001]
  • [Cites] Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60 [6167412.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):229-32 [15043733.001]
  • [Cites] Dis Colon Rectum. 1981 Nov-Dec;24(8):606-9 [6172244.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1455-61 [15486741.001]
  • [Cites] Br J Surg. 1995 Oct;82(10):1397-400 [7489177.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):11-4 [9102251.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Endoscopy. 2008 Mar;40(3):184-91 [18322873.001]
  • [Cites] Surgery. 2005 Jan;137(1):42-7 [15614280.001]
  • [Cites] Surg Gynecol Obstet. 1981 Dec;153(6):864-8 [6171042.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] Z Gastroenterol. 2004 Oct;42(10 ):1129-77 [15508058.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • (PMID = 19495779.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G: Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol; 2007 May 20;25(15):2086-92
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
  • PURPOSE: Single-agent intravenous (IV) topotecan is an effective treatment for small-cell lung cancer (SCLC) after failure of first-line chemotherapy.
  • PATIENTS AND METHODS: Patients with limited- or extensive-disease SCLC, documented complete or partial response to first-line therapy, Eastern Cooperative Oncology Group performance status < or = 2, and measurable recurrent disease (WHO criteria) with a treatment-free interval of > or = 90 days were assigned to treatment with either oral topotecan 2.3 mg/m2/d on days 1 through 5 or IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days.
  • Primary end point was response rate as confirmed by an external reviewer blinded to treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Small Cell / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Salvage Therapy. Survival Rate


50. Rochet N, Jensen AD, Sterzing F, Munter MW, Eichbaum MH, Schneeweiss A, Sohn C, Debus J, Harms W: Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol. BMC Cancer; 2007 Dec 19;7:227
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol.
  • BACKGROUND: The prognosis for patients with advanced epithelial ovarian cancer remains poor despite aggressive surgical resection and platinum-based chemotherapy.
  • More than 60% of patients will develop recurrent disease, principally intraperitoneal, and die within 5 years.
  • Despite the clinically proven efficacy of whole abdominal irradiation, the use of radiotherapy in ovarian cancer has profoundly decreased mainly due to high treatment-related toxicity.
  • Modern intensity-modulated radiation therapy (IMRT) could allow to spare kidneys, liver, and bone marrow while still adequately covering the peritoneal cavity with a homogenous dose.
  • Patients with advanced ovarian cancer stage FIGO III (R1 or R2< 1 cm) after surgical resection and platinum-based chemotherapy will be treated with whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions.
  • For treatment planning bone marrow, kidneys, liver, spinal cord, vertebral bodies and pelvic bones are defined as organs at risk.
  • DISCUSSION: The primary endpoint of the study is the evaluation of the feasibility of intensity-modulated WAI and the evaluation of the study protocol.
  • The aim is to explore the potential of IMRT as a new method for WAI to decrease the dose to kidneys, liver, bone marrow while covering the peritoneal cavity with a homogenous dose, and to implement whole abdominal intensity-modulated radiotherapy into the adjuvant multimodal treatment concept of advanced ovarian cancer FIGO stage III.
  • [MeSH-minor] Adult. Aged. Clinical Protocols. Dose Fractionation. Endpoint Determination. Feasibility Studies. Female. Humans. Middle Aged. Neoplasm Staging. Organ Specificity. Patient Selection. Pilot Projects. Radiation Injuries / prevention & control. Research Design. Risk

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1999 Dec;53(3):213-8 [10660201.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:3-11 [15839952.001]
  • [Cites] Forum (Genova). 2000 Oct-Dec;10(4):335-52 [11535984.001]
  • [Cites] Front Radiat Ther Oncol. 2002;36:25-34 [11842752.001]
  • [Cites] Radiother Oncol. 2002 Feb;62(2):163-71 [11937243.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1330-7 [11955746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):278-89 [12183002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):312-21 [12527043.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):313-21 [12742271.001]
  • [Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):278-86 [12801256.001]
  • [Cites] Radiologe. 2003 Jun;43(6):448-54 [12827259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):516-21 [12957265.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):535-41 [14509952.001]
  • [Cites] Br J Radiol. 2003 Oct;76(910):673 [14512325.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):e136-43 [14528088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1019-32 [14575833.001]
  • [Cites] Acta Oncol. 2003;42(5-6):562-6 [14596514.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:241-50 [14656286.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:135-66 [14763172.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2755-6 [15187058.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 May;8(5):893-7 [7107423.001]
  • [Cites] Cancer. 1985 May 1;55(9 Suppl):2285-90 [3919934.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):607-13 [2777649.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1203-6 [2254113.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1990 Jan;2(1):4-9 [2261388.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):30-5 [2026356.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):835-45 [1555974.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):847-51 [1555975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):853-8 [1555976.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1710-8 [8431909.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):26-32 [8438083.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii36-viii38 [16239235.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii7-viii12 [16239238.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1641-3; author reply 1641-3 [16611959.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):276-82 [16546279.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11 [16716797.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Oct;4(9):912-39 [17020669.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):783-92 [17070570.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Recent Results Cancer Res. 2007;174:91-100 [17302189.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):97-103 [8244182.001]
  • [Cites] Semin Oncol. 1995 Jun;22(3 Suppl 6):78-83 [7541158.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):543-9 [9635700.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):215-9 [10021304.001]
  • [Cites] Cancer Invest. 2004;22 Suppl 2:11-20 [15573741.001]
  • [Cites] Cancer Invest. 2004;22(5):815-7 [15581063.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):389-94 [15661226.001]
  • [Cites] Br J Radiol. 2000 May;73(869):459-69 [10884741.001]
  • (PMID = 18093313.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2212657
  •  go-up   go-down


51. Ahmad A, Chen SL, Bilchik AJ: Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases. Arch Surg; 2007 Jun;142(6):526-31; discussion 531-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: Multimodal treatment consisting of repeated hepatectomy and adjuvant systemic chemotherapy for liver-confined recurrence of colorectal cancer can yield long-term survival comparable with that associated with primary hepatectomy.
  • SETTING: A prospective database at a tertiary referral cancer center.
  • PATIENTS: Review of 274 consecutive liver resections identified 64 patients who underwent resection of hepatic colorectal metastases without ablation followed by adjuvant irinotecan hydrochloride- or oxaliplatin-based systemic chemotherapy.
  • MAIN OUTCOME MEASURES: Median and 5-year overall and disease-free survival after primary and repeated hepatectomy.
  • Multivariate analysis showed that less than 1 year between colectomy and liver resection (P = .001), more than 3 metastases (P = .001), no repeated hepatectomy (P = .01), and lymph node-positive primary colon cancer (P = .02) were independently predictive of worse survival.
  • Of 28 patients (44%) with liver-confined recurrence, 19 (30%) underwent repeated hepatectomy; at median follow-up of 38 months, median and 5-year overall survival after repeated hepatectomy were 48 months and 44%, respectively.
  • In patients with recurrence, median and 5-year overall survival measured from primary hepatectomy were 70 months and 73%, respectively, with repeated hepatectomy vs 43 months and 43%, respectively, without repeated hepatectomy (P = .03).
  • CONCLUSION: Multimodal treatment of recurrent colorectal cancer confined to the liver should begin with consideration of repeated hepatectomy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Camptothecin / analogs & derivatives. Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Organoplatinum Compounds / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17576888.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


52. El-Gendi AM, Khorsandi SE, Pai M, Zacharoulis D, Nicholls JP, Spalding DR, Jiao LR, Habib NA: Repeat hepatic resection using a radiofrequency-assisted technique. Dig Surg; 2008;25(4):293-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Repeat hepatic resection for recurrent primary or secondary liver cancer is performed due to advances in resection techniques and evidence of survival benefit.
  • The subset of patients with recurrent disease (n = 24) suitable for repeat hepatic resection had their records reviewed.
  • There were no cases of bile leak or liver failure.
  • The proportion of repeat hepatic resection for recurrent disease was high: 50% of recurrences were suitable for further resection after initial resection and 43% after second resection.
  • [MeSH-major] Catheter Ablation. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18769067.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


53. Verhoef C, Holman FA, Hussain SM, de Man RA, de Wilt JH, IJzermans JN: Resection of extrahepatic hepatocellular carcinoma metastasis can result in long-term survival. Acta Chir Belg; 2005 Sep-Oct;105(5):533-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of extrahepatic hepatocellular carcinoma metastasis can result in long-term survival.
  • Hepatocellular carcinoma (HCC) is one of the most common primary cancers in the world and the third most common cause of cancer mortality world-wide.
  • The prognosis is mainly determined by the underlying liver disease and recurrent rates.
  • In the Western World, up to 30% of the patients with HCC have a non-cirrhotic liver.
  • The role of resection in case of intrahepatic recurrences is widely accepted, particularly in the non-cirrhotic liver.
  • We present two patients with HCC in a non-cirrhotic liver with extrahepatic recurrences and long-term survival after resection.
  • The corresponding literature support an aggressive approach in case of extrahepatic HCC recurrence in selected cases: resectable metastasis, preserved liver function, absence of intracranial metastasis and control of the primary tumour.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Carcinoma, Hepatocellular / surgery. Kidney Neoplasms / secondary. Kidney Neoplasms / surgery. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver / physiology. Male. Prognosis. Recurrence. Survival. Thoracic Wall / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315842.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


54. Bilici A, Ustaalioglu BB, Seker M, Kayahan S: Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature. Clin Orthop Relat Res; 2010 Sep;468(9):2541-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Testicular cancer, like other histopathologic types, commonly metastasizes to the lungs, liver, and brain.
  • CASE DESCRIPTION: We report the case of a 38-year-old man with recurrent immature teratoma of the testis who presented with a painless soft tissue mass in the left thigh previously treated with standard chemotherapy.
  • PURPOSES AND CLINICAL RELEVANCE: We suggest that for a man with testicular cancer who has a soft tissue mass, metastasis of soft tissue from testicular cancer and other solid malignancies should be considered in the differential diagnosis of a soft tissue mass together with primary soft tissue sarcoma.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Brain Neoplasms / therapy. Chorionic Gonadotropin, beta Subunit, Human / blood. Cranial Irradiation. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Magnetic Resonance Imaging. Male. Orchiectomy. Thigh. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 2000 May;29(5):270-4 [10883446.001]
  • [Cites] Br J Radiol. 2008 Jul;81(967):e188-90 [18559897.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1644; author reply 1644 [12438072.001]
  • [Cites] Jpn J Clin Oncol. 2004 Apr;34(4):210-4 [15121758.001]
  • [Cites] Br J Surg. 1970 Jul;57(7):529-30 [5427475.001]
  • [Cites] Urology. 1985 Apr;25(4):398-400 [2984822.001]
  • [Cites] AJR Am J Roentgenol. 1985 Dec;145(6):1165-71 [2998169.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):805-8 [2820673.001]
  • [Cites] Ann Plast Surg. 1993 Oct;31(4):377-8 [8239441.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355):272-81 [9917613.001]
  • [Cites] Acta Neurol Belg. 2005 Sep;105(3):178-9 [16255156.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):885-94 [16126333.001]
  • [Cites] Singapore Med J. 2007 Mar;48(3):e77-80 [17342276.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):508-11 [17081724.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] JAMA. 2008 Feb 13;299(6):672-84 [18270356.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • (PMID = 19937408.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC2919860
  •  go-up   go-down


55. Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N: Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol; 2010 Apr;40(4):313-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
  • OBJECTIVE: The combination chemotherapy consisting of cisplatin and etoposide, one of the standard regimens for small cell lung cancer, has been widely used to treat extrapulmonary poorly differentiated neuroendocrine carcinomas.
  • However, there were no prior reports limited to the hepatobiliary tract and pancreas as the primary sites.
  • METHODS: We reviewed the cases in our database from October 1995 to January 2009 and retrospectively examined the clinical data of patients, with unresectable or recurrent poorly differentiated neuroendocrine carcinoma arising from the hepatobiliary tract and pancreas, who received combination chemotherapy with cisplatin and etoposide as the first-line treatment.
  • The primary tumor site was the liver in 2 patients, gallbladder in 8 patients, pancreas in 10 patients and ampulla of Vater in 1 patient.
  • CONCLUSIONS: Cisplatin and etoposide combination as the first-line chemotherapy for hepatobiliary or pancreatic poorly differentiated neuroendocrine carcinoma had only marginal antitumor activity and relatively severe toxicity compared with previous studies on extrapulmonary poorly differentiated neuroendocrine carcinoma treated with the same regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20047862.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


56. Habermann JK, Paulsen U, Roblick UJ, Upender MB, McShane LM, Korn EL, Wangsa D, Krüger S, Duchrow M, Bruch HP, Auer G, Ried T: Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer; 2007 Jan;46(1):10-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To identify sequential alterations of the genome, transcriptome, and proteome during colorectal cancer progression, we have analyzed tissue samples from 36 patients, including the complete mucosa-adenoma-carcinoma sequence from 8 patients.
  • Comparative genomic hybridization (CGH) revealed patterns of stage specific, recurrent genomic imbalances.
  • Gene expression analysis on 9K cDNA arrays identified 58 genes differentially expressed between normal mucosa and adenoma, 116 genes between adenoma and carcinoma, and 158 genes between primary carcinoma and liver metastasis (P < 0.001).
  • In conclusion, increasing genomic instability and a recurrent pattern of chromosomal imbalances as well as specific gene and protein expression changes correlate with distinct stages of colorectal cancer progression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Models, Biological. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Wiley-Liss, Inc.
  • (PMID = 17044061.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteome
  •  go-up   go-down


57. Kinugasa Y, Morishige K, Kamiura S, Tsukamoto Y, Saji F: Parathyroid hormone-related protein-secreting uterine endometrioid adenocarcinoma. Jpn J Clin Oncol; 2006 Feb;36(2):113-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of parathyroid hormone-related protein (PTHrP)-secreting metastatic uterine endometrioid cancer was made in a 32-year-old Japanese woman with humoral hypercalcemia of malignancy.
  • The primary endometrial cancer had been removed, and the tumor was diagnosed as Grade 1 endometrioid adenocarcinoma with shallow myometrial invasion.
  • Salvage chemotherapy (paclitaxel and calboplatin) was started from 5 months after surgery when recurrent tumors were detected in the peritoneum and liver.
  • [MeSH-major] Carcinoma, Endometrioid / chemistry. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / pathology. Hypercalcemia / etiology. Parathyroid Hormone-Related Protein / analysis
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Immunohistochemistry. Japan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418186.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


58. Veriasova NN, Polysalov VN, Ivanova AA, Krotova OA, Urbanskiĭ AI: [Combined treatment for malignant tumors using focal ethanol injections]. Vopr Onkol; 2007;53(2):200-5
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-four patients with inoperable primary and recurrent liver cancer received 72 FEIT procedures at the Institute's Clinic - 16 males (47%) and 18 females (53%), aged 35-80, (average 57), (1991-2004).
  • Forty-three metastatic foci - colorectal carcinoma (23), non-colorectal carcinoma (20) and hepatocellular carcinoma (11) - were detected.
  • Size of metastatic foci ranged 3.2-27.8 cm3 (average 15.4+/-6.4 cm3), while those of hepatocellular carcinoma - 156.7-982.4 cm3, (average 492.4+/-136.8 cm3).
  • Reduction in focal size after FEIT for hepatocellular carcinoma ranged 490.2+/-136.8 - 41.8+/-14 cm3.
  • In cases of hepatocellular carcinoma, ethanol-treated foci shrank by 88.4% - from 15.5+/-1.6 to 1.8 +/- 0.3 cm3 (p<0.05).
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Ethanol / administration & dosage. Liver Neoplasms / therapy. Sclerosing Solutions / administration & dosage. Sclerotherapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colorectal Neoplasms / pathology. Female. Humans. Injections, Intralesional. Male. Middle Aged. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663175.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Sclerosing Solutions; 3K9958V90M / Ethanol
  •  go-up   go-down


59. Yan K, Chen MH, Yang W, Wang YB, Gao W, Hao CY, Xing BC, Huang XF: Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol; 2008 Aug;67(2):336-47
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors.
  • PURPOSE: To investigate the efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), and the prognostic factors for post-RFA survival rate.
  • For the 58 patients with post-surgery recurrent HCC, the survival rates were 73.2%, 41.9% and 38.2% at the 1st, 3rd, and 5th year, which were significantly lower than those of stage I HCC (P=0.005).
  • Nine potential factors were found with significant effects on survival rate, and they were number of tumors, location of tumors, pre-RFA liver function enzymes, Child-Pugh classification, AJCC staging, primary or recurrent HCC, tumor pathological grading, using mathematical protocol in RFA procedure and tumor necrosis 1 month after RFA.
  • This long-term follow-up study on a large group of HCC patients confirmed that RFA could not only achieve favorable outcome on stage I HCC, but also be an effective therapy for stage II-IV or recurrent HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765421.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


60. Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M: Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg; 2007 Oct-Dec;70(4):331-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were divided into 2 groups: diagnosis and staging of primary tumours (n=34) and restaging: screening for recurrent or progressive pancreatic cancer (n=12).
  • Thirty-four lesions were defined as 'definitely pathologic' and localised in pancreas, liver, lung or bone by all 3 techniques with equal certainty.
  • The accuracy rate of PET/CT (91.2%) for diagnosis of primary pancreatic lesions is higher compared to CT (88.2%) and PET alone (82.3%).
  • Fused PET/CT has a slightly higher sensitivity and accuracy rate for diagnosis and locoregional staging of primary pancreatic lesions compared to CT alone.
  • PET and PET/CT perform equally well in screening for recurrent or progressive pancreatic cancer, with high accuracy.
  • Due to its unlimited access, lower radiation exposure and cost, multidetector row CT remains the imaging technique of choice for diagnosis, staging and screening for recurrent pancreatic cancer.
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / diagnosis. Disease Progression. False Positive Reactions. Female. Follow-Up Studies. Humans. Liver Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18330088.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


61. Schulz-Utermoehl T, Spear M, Pollard CR, Pattison C, Rollison H, Sarda S, Ward M, Bushby N, Jordan A, Harrison M: In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos; 2010 Oct;38(10):1688-97

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro metabolism of cediranib (4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline), a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) of all three VEGF receptors in late-stage development for the treatment of colorectal cancer and recurrent glioblastoma was investigated in hepatic proteins from preclinical species and humans using radiolabeled material.
  • The primary oxidative pathways were di-and trioxidations and pyrrolidine N-oxidation.
  • Additional metabolism studies in liver microsomes from these or other preclinical species (CD-1 mouse, Han Wistar rat, Dunkin Hartley guinea pig, Göttingen mini-pig, New Zealand White rabbit, beagle dog, and cynomolgus and rhesus monkey) indicated that the N(+)-glucuronide metabolite was not formed in these additional species.
  • [MeSH-major] Liver / enzymology. Liver / metabolism. Quinazolines / pharmacokinetics. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adult. Animals. Cells, Cultured. Cytochrome P-450 Enzyme System / metabolism. Dogs. Female. Glucuronosyltransferase / metabolism. Guinea Pigs. Hepatocytes / enzymology. Hepatocytes / metabolism. Humans. Macaca fascicularis. Macaca mulatta. Male. Metabolic Detoxication, Phase I. Metabolic Detoxication, Phase II. Mice. Microsomes, Liver / enzymology. Microsomes, Liver / metabolism. Middle Aged. Oxygenases / metabolism. Rabbits. Rats. Rats, Wistar. Species Specificity. Swine. Swine, Miniature

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20634336.001).
  • [ISSN] 1521-009X
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.13.- / Oxygenases; EC 1.14.13.8 / dimethylaniline monooxygenase (N-oxide forming); EC 2.4.1.17 / Glucuronosyltransferase; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; NQU9IPY4K9 / cediranib
  •  go-up   go-down


62. Bo JG, Yang XP: [Precise orientation and hepatectomy in the management of biliary tract hemorrhage]. Zhonghua Yi Xue Za Zhi; 2009 May 26;89(20):1408-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Clinical data of 23 patients with biliary tract hemorrhage undergoing liver segmentectomy between January 1998 and October 2008 were analyzed.
  • There were infection of biliary tract or hepatolithiasis in 14 patients (60.9%), trauma in 6 (26.1%) and primary liver cancer in 3 (10.0%).
  • During the follow-up period of 8 months-10 years in 15 patients, 3 died of recurrent or metastasis liver cancer and 2 biliary cirrhosis.
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671336.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Sun HC, Tang ZY, Ma ZC, Qin LX, Wang L, Ye QH, Fan J, Wu ZQ, Zhou XD: The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background. J Cancer Res Clin Oncol; 2005 May;131(5):284-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background.
  • PURPOSE: Second resection has been proved to be a safe and effective treatment for patients with intrahepatic recurrent HCC after primary resection; however, preoperative prognostic factors for outcome following second resection in patients with a hepatitis B virus (HBV) infection background remains to be clarified.
  • METHODS: Fifty-seven patients with intrahepatic recurrent an HCC and HBV infection background received second resection from 1997 to 2003 in our institute.
  • CONCLUSIONS: Vascular invasion and time to recurrence were the prognostic factors for overall survival following second resection of intrahepatic recurrent HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatitis B / complications. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Reoperation. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2003 Nov;197(5):753-8 [14585409.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(5):417-21 [11702250.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):127-31 [8653337.001]
  • [Cites] Ann Chir. 1998;52(6):558-63 [9752506.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5193-9 [15289324.001]
  • [Cites] J Am Coll Surg. 2003 Nov;197(5):759-64 [14585410.001]
  • [Cites] Arch Surg. 1998 Feb;133(2):183-8 [9484732.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(5):410-6 [11702249.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):644-50 [8799409.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):536-41 [2544255.001]
  • [Cites] Ann Surg. 2003 Nov;238(5):711-9 [14578734.001]
  • [Cites] Lancet. 2000 Sep 2;356(9232):802-7 [11022927.001]
  • [Cites] Folia Neuropathol. 2004;42(1):49-53 [15119746.001]
  • [Cites] J Am Coll Surg. 2000 Oct;191(4):381-8 [11030243.001]
  • [Cites] J Hepatol. 2003 Feb;38(2):200-7 [12547409.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):320-3 [8406299.001]
  • [Cites] Ann Intern Med. 2001 May 15;134(10):963-7 [11352697.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):216-22 [10024103.001]
  • [Cites] Ann Surg. 2003 Nov;238(5):703-10 [14578733.001]
  • [Cites] Hepatology. 2000 Aug;32(2):228-32 [10915728.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):887-97 [12788425.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1188-91; discussion 1192 [1333684.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):86-92 [9683759.001]
  • [Cites] J Am Coll Surg. 2001 Mar;192(3):339-44 [11245376.001]
  • [Cites] J Surg Oncol. 1990 Mar;43(3):181-8 [2179631.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):63-70 [11420484.001]
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):311-8 [12229937.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):373-82 [11882759.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):500-7 [10931448.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):122-6 [7881929.001]
  • [Cites] Br J Surg. 1996 Mar;83(3):336-40 [8665186.001]
  • [Cites] Hepatology. 1997 Jan;25(1):87-92 [8985270.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(1):81-6 [11294294.001]
  • [Cites] N Engl J Med. 2002 Jul 18;347(3):168-74 [12124405.001]
  • [Cites] N Engl J Med. 1996 Jun 13;334(24):1561-7 [8628336.001]
  • (PMID = 15662524.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


64. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut; 2007 Jun;56(6):772-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer.
  • (c) first degree relatives of patients with gastric cancer;.
  • Recurrent abdominal pain in children is not an indication for a "test and treat" strategy if other causes are excluded.
  • In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45.
  • CONCLUSION: The global burden of gastric cancer is considerable but varies geographically.
  • Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Child. Drug Resistance, Bacterial. Dyspepsia / microbiology. Gastroesophageal Reflux / microbiology. Humans. Lymphoma, B-Cell, Marginal Zone / microbiology. Stomach Neoplasms / microbiology. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):4-10 [14744726.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 15;19(4):407-14 [14871280.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):273-8 [15017668.001]
  • [Cites] Am J Gastroenterol. 2004 May;99(5):823-9 [15128344.001]
  • [Cites] Helicobacter. 2004 Aug;9(4):342-6 [15270749.001]
  • [Cites] Helicobacter. 2004 Aug;9(4):347-68 [15270750.001]
  • [Cites] Dig Liver Dis. 2004 Jul;36(7):455-60 [15285524.001]
  • [Cites] Gut. 2004 Sep;53(9):1374-84 [15306603.001]
  • [Cites] Br J Cancer. 1989 May;59(5):810-3 [2736218.001]
  • [Cites] Gut. 1992 Sep;33(9):1166-9 [1358764.001]
  • [Cites] Am J Gastroenterol. 1995 Nov;90(11):1965-8 [7485001.001]
  • [Cites] Scand J Gastroenterol Suppl. 1997;223:28-34 [9200303.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):639-42 [9264278.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] J Clin Microbiol. 1998 Oct;36(10):2803-9 [9738024.001]
  • [Cites] Lancet. 1998 Sep 12;352(9131):878 [9742983.001]
  • [Cites] Lancet. 1998 Sep 26;352(9133):1016-21 [9759744.001]
  • [Cites] Am J Gastroenterol. 1999 Mar;94(3):725-9 [10086658.001]
  • [Cites] Aliment Pharmacol Ther. 1999 May;13(5):667-73 [10233191.001]
  • [Cites] Lancet. 2001 Jun 9;357(9271):1851-3 [11410197.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Jul;15(7):1067-76 [11421884.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5415-9 [11454685.001]
  • [Cites] Gut. 2001 Sep;49(3):347-53 [11511555.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1405-10 [11562392.001]
  • [Cites] Arch Intern Med. 2001 Sep 24;161(17):2129-32 [11570943.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):784-91 [11606491.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1120-6 [11677204.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2829-38 [11693315.001]
  • [Cites] Am J Gastroenterol. 1996 Jun;91(6):1138-44 [8651160.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1996 Aug;8(8):811-3 [8864680.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Jan;9(1):1-2 [9031888.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2001 Nov;20(11):820-3 [11783701.001]
  • [Cites] Lancet. 2002 Jan 5;359(9300):9-13 [11809180.001]
  • [Cites] Lancet. 2002 Jan 5;359(9300):14-22 [11809181.001]
  • [Cites] Helicobacter. 2001 Dec;6(4):294-9 [11843961.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Feb;16(2):167-80 [11860399.001]
  • [Cites] BMJ. 2002 Apr 27;324(7344):1012-6 [11976244.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1270-85 [11984514.001]
  • [Cites] Occup Environ Med. 2002 May;59(5):329-37 [11983848.001]
  • [Cites] N Engl J Med. 2002 Jun 27;346(26):2033-8 [12087138.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):181-6; discussion 186-7 [12168964.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Aug;16(8):1431-42 [12182742.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):747-9 [12190084.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Oct;16(10):1733-8 [12269965.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2756-62 [12425544.001]
  • [Cites] Am J Gastroenterol. 2002 Dec;97(12):2992-7 [12492181.001]
  • [Cites] Diabetes Care. 2003 Jan;26(1):82-8 [12502662.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jan;17(2):193-200 [12534403.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Feb;17(3):297-305 [12562442.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):291-5 [12591043.001]
  • [Cites] Helicobacter. 1999 Jun;4(2):106-12 [10382124.001]
  • [Cites] Gastroenterology. 1999 Jul;117(1):257-61 [10381935.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2380-3 [10483995.001]
  • [Cites] Ann Intern Med. 1999 Nov 2;131(9):668-72 [10577329.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Nov 15;20(10):1001-17 [15569102.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Nov 15;20(10):1071-82 [15569109.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):453-9 [15667507.001]
  • [Cites] Int J Hematol. 2005 Feb;81(2):162-8 [15765787.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Jun 15;21(12):1411-8 [15948807.001]
  • [Cites] Can J Gastroenterol. 2005 Jul;19(7):399-408 [16010300.001]
  • [Cites] Am J Gastroenterol. 2005 Sep;100(9):2100-15 [16128957.001]
  • [Cites] Ann Hematol. 2005 Nov;84(12):807-11 [16078036.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jan 1;23(1):35-44 [16393278.001]
  • [Cites] Am J Gastroenterol. 2006 Mar;101(3):488-96 [16542284.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):101-5 [10638566.001]
  • [Cites] Gastroenterol Clin North Am. 1999 Dec;28(4):971-85, viii [10695012.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2000 Feb;30(2):207-13 [10697142.001]
  • [Cites] Scand J Gastroenterol. 2000 Feb;35(2):138-41 [10720110.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Mar;14(3):291-7 [10735921.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] Gut. 2000 May;46(5):615-21 [10764703.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1691-8 [10925969.001]
  • [Cites] BMJ. 2000 Sep 16;321(7262):659-64 [10987767.001]
  • [Cites] J Clin Microbiol. 2000 Oct;38(10):3710-4 [11015388.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Oct;14 Suppl 3:13-22 [11050483.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Oct;15(10):1105-12 [11106088.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1881-8 [11106679.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Dec;14(12):1639-43 [11121913.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):967-73 [11274623.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Mar 1;17(5):719-26 [12641522.001]
  • [Cites] Chin Med J (Engl). 2003 Jan;116(1):11-4 [12667379.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jun 1;17(11):1333-43 [12786627.001]
  • [Cites] Am J Gastroenterol. 2003 May;98(5):1005-9 [12809820.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):235-9 [12824915.001]
  • [Cites] Can J Gastroenterol. 2003 Jun;17 Suppl B:36B-40B [12845349.001]
  • [Cites] Am J Gastroenterol. 2003 Jul;98(7):1462-70 [12873564.001]
  • [Cites] Ann Intern Med. 2003 Sep 16;139(6):463-9 [13679322.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Oct 15;18(8):791-7 [14535872.001]
  • [Cites] Gut. 2004 Jan;53(1):12-20 [14684569.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2621-6 [14687807.001]
  • [Cites] JAMA. 2004 Jan 14;291(2):187-94 [14722144.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1636-44 [14724815.001]
  • (PMID = 17170018.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 99
  • [Other-IDs] NLM/ PMC1954853
  •  go-up   go-down


65. Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF Jr, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA, Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare: A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1035-41
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors.
  • Gemcitabine (2',2'-difluorodeoxycytidine) is a novel purine analog with clinical activity against ovarian cancer.
  • Women with ovarian, fallopian tube, or primary peritoneal carcinoma and documented recurrent disease were eligible for the study.
  • Although 43% were Eastern Cooperative Oncology Group 0, 50% had liver metastases.
  • FDR-gemcitabine 700 mg/m2 administered by intravenous infusion at an FDR of 10 mg/m2/min had minimal activity against heavily pretreated recurrent tumors of müllerian origin.
  • [MeSH-minor] Adult. Aged. Carboplatin / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343179.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


66. Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, Lee JH, Bae DS: Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1084-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pelvis (eight cases) was the most common site of recurrence followed by the lung (four cases) and the liver (one case).
  • Recurrent disease was treated with surgery (one case), surgery plus chemotherapy (five cases), chemotherapy (two cases), and surgery plus radiotherapy (two cases).
  • Surgery is the primary treatment for recurrent endometrial stromal sarcoma when feasible.
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179547.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D'Angelica M, Abou-Alfa G, Blumgart LH, DeMatteo RP: Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer; 2006 Mar 15;106(6):1331-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with fibrolamellar hepatocellular carcinoma.
  • BACKGROUND: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare variant of hepatocellular carcinoma, has distinct pathologic features, and typically occurs in young patients without underlying hepatitis or cirrhosis.
  • Twenty-eight patients with primary disease underwent complete gross resection, and 13 patients were unresectable.
  • Seventeen (61%) patients underwent a second operation for recurrent disease.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Fibrolamellar carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16475212.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Nakahara Y, Northcott PA, Li M, Kongkham PN, Smith C, Yan H, Croul S, Ra YS, Eberhart C, Huang A, Bigner D, Grajkowska W, Van Meter T, Rutka JT, Taylor MD: Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia; 2010 Jan;12(1):20-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have identified rare, recurrent homozygous deletions of Kruppel-like Factor 4 (KLF4) in medulloblastoma using high-resolution single nucleotide polymorphism arrays, digital karyotyping, and genomic real-time polymerase chain reaction (PCR).
  • Furthermore, we show that there is loss of physiological KLF4 expression in more than 40% of primary medulloblastomas both at the RNA and protein levels.
  • Methylation-specific PCR targeting the KLF4 promoter demonstrates CpG methylation in approximately 16% of primary medulloblastomas.
  • [MeSH-minor] Adult. Animals. Antimetabolites, Antineoplastic / pharmacology. Azacitidine / pharmacology. Cell Line, Tumor. CpG Islands / genetics. DNA Methylation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Kaplan-Meier Estimate. Loss of Heterozygosity. Mice. Mice, Nude. Neoplasms, Experimental / genetics. Neoplasms, Experimental / pathology. Oligonucleotide Array Sequence Analysis. Polymorphism, Single Nucleotide. Promoter Regions, Genetic / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 2001 Aug 30;31(4):557-68 [11545715.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3249-55 [19351822.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):395-402 [14724568.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2709-19 [15102675.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3444-53 [15064731.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):168-78 [15140406.001]
  • [Cites] Oncogene. 2004 Jun 3;23(26):4577-83 [15077159.001]
  • [Cites] Neoplasia. 2004 Jul-Aug;6(4):310-22 [15256053.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6002-9 [15342380.001]
  • [Cites] Development. 1999 May;126(9):1927-35 [10101126.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):919-24 [15705891.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4542-7 [15761058.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2746-54 [15805274.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):575-84 [16036108.001]
  • [Cites] Nat Cell Biol. 2005 Nov;7(11):1074-82 [16244670.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):11-23 [16372018.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11579-83 [16864777.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Childs Nerv Syst. 2006 Nov;22(11):1379-94 [16951964.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):267-74 [17579622.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7147-54 [17671182.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4679-84 [17878366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14935-40 [17846424.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):89-98 [18231642.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4631-9 [18559508.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):736-44 [18592012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16224-9 [18852474.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9945-53 [19047176.001]
  • [Cites] Neoplasia. 2008 Dec;10(12):1343-9, 5p following 1349 [19048113.001]
  • [Cites] Neuro Oncol. 2008 Dec;10(6):981-94 [18664619.001]
  • [Cites] Neoplasia. 2009 Jan;11(1):96-101 [19107236.001]
  • [Cites] Mol Cancer Res. 2009 Jan;7(1):33-40 [19147535.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G490-8 [19109406.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):465-72 [19270706.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):719-24 [19360079.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):198-204 [12869303.001]
  • (PMID = 20072650.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS055089
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC2805880
  •  go-up   go-down


69. Santambrogio R, Opocher E, Costa M, Bruno S, Ceretti AP, Spina GP: Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World J Gastroenterol; 2006 Oct 21;12(39):6331-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To compare endoscopic sclerotherapy (ES) with distal splenorenal shunt (DSRS) in the prevention of recurrent variceal bleeding in cirrhotic patients during a long-term follow-up period.
  • METHODS: In 1984 we started a prospective, controlled study of patients with liver cirrhosis.
  • Long-term follow-up presents a natural history of liver cirrhosis complicated by advanced portal hypertension.
  • One DSRS patient had mild recurrent variceal hemorrhage despite an angiographically patent DSRS and another patient suffered duodenal ulcer rebleeding.
  • The primary cause of death became hepatocellular carcinoma (HCC).
  • Four DSRS patients rebled due to duodenal ulcer, while eleven ES patients had recurrent bleeding from esophago-gastric sources (seven from varices, three from hypertensive gastropathy, one from esophageal ulcerations) and two from unknown sources.
  • CONCLUSION: In a subgroup of patients with good liver function, DSRS with a correct portal-azygos disconnection more effectively prevents variceal rebleeding than ES.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Esophageal and Gastric Varices / prevention & control. Gastrointestinal Hemorrhage / prevention & control. Liver Cirrhosis / complications. Sclerotherapy / methods. Splenorenal Shunt, Surgical / methods
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Hypertension, Portal / complications. Hypertension, Portal / physiopathology. Longitudinal Studies. Male. Middle Aged. Randomized Controlled Trials as Topic. Secondary Prevention. Survival Rate

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1980 Jan;139(1):132-41 [7350837.001]
  • [Cites] Ann Surg. 1977 Feb;185(2):224-8 [300005.001]
  • [Cites] Gastroenterology. 1981 Apr;80(4):800-9 [6970703.001]
  • [Cites] Ann Surg. 1982 May;195(5):530-42 [7073351.001]
  • [Cites] Hepatology. 1983 Sep-Oct;3(5):681-4 [6352448.001]
  • [Cites] Lancet. 1983 Dec 10;2(8363):1328-32 [6139669.001]
  • [Cites] N Engl J Med. 1984 Dec 20;311(25):1594-600 [6390203.001]
  • [Cites] World J Surg. 1984 Oct;8(5):722-32 [6390991.001]
  • [Cites] Hepatology. 1985 Jul-Aug;5(4):584-9 [3894200.001]
  • [Cites] Hepatology. 1985 Sep-Oct;5(5):827-30 [2993147.001]
  • [Cites] Gut. 1986 Jun;27(6):710-3 [3522372.001]
  • [Cites] Br J Surg. 1986 Sep;73(9):708-11 [3756433.001]
  • [Cites] Ann Surg. 1986 Oct;204(4):346-55 [3532968.001]
  • [Cites] Hepatology. 1987 Mar-Apr;7(2):355-61 [3549507.001]
  • [Cites] Hepatology. 1987 May-Jun;7(3):430-6 [3552920.001]
  • [Cites] Hepatology. 1987 May-Jun;7(3):437-41 [3552921.001]
  • [Cites] Surg Gynecol Obstet. 1987 Jun;164(6):530-6 [3495894.001]
  • [Cites] Int Surg. 1987 Jul-Sep;72(3):144-8 [3679731.001]
  • [Cites] Am J Surg. 1988 Apr;155(4):564-71 [3354781.001]
  • [Cites] Ann Surg. 1988 Jul;208(1):104-9 [3389941.001]
  • [Cites] Ann Intern Med. 1990 Feb 15;112(4):262-9 [2404448.001]
  • [Cites] Ann Surg. 1990 Feb;211(2):178-86 [2405792.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):27-32; discussion 32-3 [8418700.001]
  • [Cites] J Hepatol. 1992 Nov;16(3):338-45 [1487611.001]
  • [Cites] Radiology. 1999 Aug;212(2):411-21 [10429698.001]
  • [Cites] Hepatology. 1999 Sep;30(3):612-22 [10462365.001]
  • [Cites] Dig Liver Dis. 2004 Dec;36(12):787-98 [15646423.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):238-46 [15650633.001]
  • [Cites] J Chin Med Assoc. 2004 Nov;67(11):557-64 [15720069.001]
  • [Cites] Hepatology. 2005 Mar;41(3):566-71 [15726654.001]
  • [Cites] Gastroenterology. 1977 Apr;72(4 Pt 1):573-83 [14049.001]
  • [Cites] Semin Liver Dis. 1999;19(4):439-55 [10643628.001]
  • [Cites] Surgery. 2000 Jun;127(6):614-21 [10840355.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):17-20 [11146768.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1110-3 [11490812.001]
  • [Cites] Stat Med. 2003 Feb 28;22(4):559-71 [12590414.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S54-68 [12591186.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):437-55 [6068492.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Jpn J Surg. 1980 Mar;10(1):84-7 [7373958.001]
  • (PMID = 17072957.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088142
  •  go-up   go-down


70. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer; 2005 Mar 15;103(6):1201-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.
  • BACKGROUND: Radiofrequency ablation (RFA) was introduced recently as a therapeutic modality for hepatocellular carcinoma (HCC), an alternative to percutaneous ethanol injection therapy (PEIT), which is coming into use worldwide.
  • Cumulative survival was also assessed in 319 patients who received RFA as primary treatment (naive patients) and 345 patients who received RFA for recurrent tumor after previous treatment including resection, PEIT, microwave coagulation therapy, and transarterial embolization (nonnaive patients).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / mortality. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / epidemiology. Prevalence. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sex Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690326.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R, Putzer D, Gabriel M, Virgolini I: Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging; 2010 Feb;54(1):52-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eleven patients (3 non small cell lung cancer [NSCLC], 3 small cell lung cancer [SCLC], 3 radioiodine negative thyroid cancer, 2 medullary thyroid cancer [MTC]) were investigated.
  • Comparison of positron emission tomography (PET) and CIT showed concordant results in 3/8 patients and partial concordant results in 5/8 patients with matched results for the primary/recurrent tumor, mediastinal lymph nodes, or adrenal gland metastases.
  • Partial concordant results were seen for the lung, bone, liver and cervical lymph node metastases.
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Female. Gallium Radioisotopes / adverse effects. Gallium Radioisotopes / chemistry. Gallium Radioisotopes / pharmacokinetics. Humans. Image Interpretation, Computer-Assisted. Lung Neoplasms / metabolism. Lung Neoplasms / radionuclide imaging. Male. Middle Aged. Receptors, Somatostatin / metabolism. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology. Thyroid Neoplasms / radionuclide imaging

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168286.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Heterocyclic Compounds, 1-Ring; 0 / Peptides, Cyclic; 0 / Receptors, Somatostatin; 0 / gallium 68-DOTA-lanreotide; 51110-01-1 / Somatostatin
  •  go-up   go-down


72. Scoccianti S, Detti B, Sardaro A, Iannalfi A, Meattini I, Leonulli BG, Borghesi S, Martinelli F, Bordi L, Ammannati F, Biti G: Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs; 2008 Jul;19(6):613-20
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate efficacy and safety of fotemustine chemotherapy in temozolomide (TMZ) pretreated adults with recurrent glioblastoma multiforme (GBM).
  • Primary endpoint was progression-free survival at 6 months.
  • Twenty-seven patients (median age: 56 years; median Karnofsky performance status at progression: 80) with relapsed glioblastoma multiforme underwent fotemustine as second-line chemotherapy after failure of homogeneous postoperative treatment consisting of conformal radiotherapy (60 Gy in 30 fractions) with concomitant TMZ (75 mg/m2 per day), followed by six courses of TMZ (150-200 mg/m2 for 5 days every 28 days).
  • Adequate liver, renal, and bone marrow functions were required.
  • Toxicity grading was based on the National Cancer Institute's Common Toxicity Criteria (version 2.0).
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525321.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; GQ7JL9P5I2 / fotemustine
  •  go-up   go-down


73. Murakami M, Tsukada H, Shida M, Watanabe M, Maeda H, Koido S, Hirasawa T, Muramatsu T, Miyamoto T, Nasu S, Yasuda S, Kajiwara H, Yasuda M, Ide M: Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):854-60
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the usefulness of whole-body positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG-PET) for the detection of recurrence in follow-up patients after primary treatment of uterine sarcoma.
  • PET revealed recurrent sites in the intraperitoneum, liver, lung, bone, and retroperitoneal lymph nodes.
  • Positive PET findings did not affect the prognosis in three of the five recurrent patients; however, the remaining two patients consequently underwent the combination therapy consisting of surgery and chemotherapy and survived for more than 1 year after the positive FDG-PET results.
  • Application of PET imaging for the early detection of recurrent sites was useful for the decision of treatment strategy for patients with recurrent uterine sarcoma.
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681773.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


74. Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini EH, Wagner AJ, Demetri GD, Raut CP: Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol; 2007 Dec;14(12):3534-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty patients (60% women, median age 57 years) with primary IVC LMS were treated with curative intent.
  • All patients underwent resection of the primary tumor; one was found to have unresectable liver metastases.
  • The IVC was managed with ligation (3), primary repair (12), or prosthetic graft (5).
  • CONCLUSIONS: Patients with IVC LMS treated with curative intent develop early recurrent disease.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17896156.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement